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The RH5.1/AS01B vaccine is safe,
well tolerated, and immunogenic
in healthy adults
A delayed fractional third dose
significantly improves antibody
response longevity
In vivo blood-stage P. falciparum
growth rate is significantly lower in
vaccinees
In vitro IgG-mediated growth
inhibition activity is associated
with challenge outcomeMinassian et al. report that the RH5.1/AS01B vaccine against blood-stage
Plasmodium falciparum malaria is safe and immunogenic in a phase I/IIa clinical
trial. They demonstrate a significantly reduced blood-stage parasite growth rate in
vaccinees following controlled human malaria infection and identify that in vitro
antibody-mediated growth inhibition activity is associated with challenge
outcome.Minassian et al., Med 2, 701–719
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Carter L. Diggs,11 Lorraine A. Soisson,11 Rebecca Ashfield,1 Saul N. Faust,7 Anna L. Goodman,6
Alison M. Lawrie,1 Fay L. Nugent,1 Galit Alter,3 Carole A. Long,2 and Simon J. Draper1,13,*Context and significance
A highly effective vaccine against
the human malaria parasite
Plasmodium falciparum is
urgently needed. One vaccine
strategy aims to prevent parasite
growth in the blood, protecting
against clinical disease; however,
this has proved exceptionally
challenging. Here we show that a
candidate vaccine (reticulocyte-
binding protein homolog 5.1
[RH5.1]/AS01B) is safe in a phase I/
IIa clinical trial and identify a
vaccination regimen that
improves the durability of the
human antibody response, which
is critical for long-term protection.
Following experimental challenge
of vaccinated adults with malaria,
we observed that the vaccine
could reduce parasite growth in
the blood and identified immune
responses that could predict how
well the vaccine performs. These
data will help guide the design of
improved vaccines in the future.SUMMARY
Background: Development of an effective vaccine against the patho-
genic blood-stage infection of human malaria has proved challenging,
and no candidate vaccine has affected blood-stage parasitemia
following controlled human malaria infection (CHMI) with blood-stage
Plasmodium falciparum.
Methods: We undertook a phase I/IIa clinical trial in healthy adults
in the United Kingdom of the RH5.1 recombinant protein vaccine, tar-
geting the P. falciparum reticulocyte-binding protein homolog 5
(RH5), formulated in AS01B adjuvant. We assessed safety, immunoge-
nicity, and efficacy against blood-stage CHMI. Trial registered at
ClinicalTrials.gov, NCT02927145.
Findings: The RH5.1/AS01B formulation was administered using a range
of RH5.1 protein vaccine doses (2, 10, and 50 mg) and was found to
be safe and well tolerated. A regimen using a delayed and fractional
third dose, in contrast to three doses given at monthly intervals, led
to significantly improved antibody response longevity over 2 years
of follow-up. Following primary and secondary CHMI of vaccinees
with blood-stage P. falciparum, a significant reduction in parasite
growth rate was observed, defining amilestone for the blood-stagema-
laria vaccine field. We show that growth inhibition activity measured
in vitro using purified immunoglobulin G (IgG) antibody strongly corre-
lates with in vivo reduction of the parasite growth rate and also identify
other antibody feature sets by systems serology, including the plasma
anti-RH5 IgA1 response, that are associated with challenge outcome.
Conclusions: Our data provide a new framework to guide rational
design and delivery of next-generation vaccines to protect against
malaria disease.
Funding: This study was supported by USAID, UK MRC, Wellcome
Trust, NIAID, and the NIHR Oxford-BRC.Med 2, 701–719, June 11, 2021 ª 2021 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS Clinical AdvancesINTRODUCTION
Despite major advances in malaria control, estimates in 2018 suggest that there
were still 228 million clinical cases leading to 405,000 deaths.1 Consequently, there
remains a pressing need for a highly effective and durable vaccine.2 Encouragingly,
whole-parasite and subunit strategies targeting the invasive sporozoite and/or liver
stage of Plasmodium falciparum have shown moderate levels of efficacy in field
trials.3 However, these approaches continue to face various challenges related to
durability or breadth of protection and immunopotency in target populations.
They also necessitate sterilizing immunity to prevent the subsequent pathogenic
blood stage of infection. An alternative and complementary approach is to vaccinate
against the blood-stage merozoite leading to inhibition of erythrocyte invasion and,
thus, control and/or clearance of blood-stage parasitemia, protecting against
morbidity and mortality and reducing transmission.3 However, historical efforts to
develop anti-merozoite vaccines have been thwarted by substantial levels of target
antigen polymorphism,4 redundancy of erythrocyte invasion pathways,5 and a poor
understanding of immune mechanisms that can provide in vivo protection in
humans.
Nonetheless, substantial progress has been made in recent years following identifi-
cation of an essential, highly conserved, antibody-susceptible, heterotrimeric pro-
tein complex used by P. falciparum merozoites to invade erythrocytes.6 Vaccine
development efforts are most advanced for one component of the complex, called
RH5.3 This vaccine target binds basigin on the erythrocyte surface,7 an indispensable
receptor-ligand interaction linked to host erythrocyte tropism of P. falciparum8 and
one the parasite has evolved to shield from the immune system. Indeed, RH5 ap-
pears to be poorly immunogenic in the context of natural malaria infection,9–12 likely
explaining its relatively high degree of sequence conservation. Conversely, vaccina-
tion of mice, rats, and rabbits with full-length RH5 (RH5_FL) induces high levels of
functional antibodies that inhibit in vitro growth of all tested P. falciparum laboratory
lines and isolates,9,13–15 notably with higher efficiency than other historical target an-
tigens, such as merozoite surface protein 1 (MSP1) and apical membrane antigen 1
(AMA1).13,16 Additionally, significant in vivo protection has been demonstrated
against a stringent blood-stage P. falciparum challenge in Aotus monkeys.17 These
data provided momentum to advance RH5-based vaccines into clinical testing.
Expression of RH5_FL protein proved challenging for a number of years, and, conse-
quently, the first vaccine regimen that progressed to phase Ia clinical testing
(VAC057; ClinicalTrials.gov: NCT02181088) utilized a recombinant prime-boost vi-
rus-vectored delivery platform that enabled in situ expression of RH5_FL by virally
infected cells.11 This regimen was well tolerated and induced functional antibodies
that exhibited cross-strain in vitro growth inhibition activity (GIA). However,
although the levels of anti-RH5_FL serum immunoglobulin G (IgG) in this trial greatly
exceeded those observed in naturally exposed African adults, they still only peaked
at moderate concentrations of 9 mg/mL.11 Notably, our study in Aotus monkeys
predicted these to fall below a protective immunological threshold, and we there-
fore elected not to proceed to efficacy testing by blood-stage controlled humanma-
laria infection (CHMI).18 Indeed, protection in Aotus monkeys was strongly associ-
ated with anti-RH5_FL serum IgG antibody concentration and in vitro GIA
measured using purified IgG,17 with high-level protection only achieved when using
a recombinant RH5_FL protein-in-adjuvant formulation.17 Subsequently, we suc-
cessfully expressed recombinant RH5_FL by using a Drosophila S2 stable cell
line19,20 (a platform compatible with human delivery) and were therefore able to
https://doi.org/10.1016/j.medj.2021.03.014
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Figure 1. Antibody immunogenicity of RH5.1/AS01B
(A) Timing of immunizations and follow-up in groups 1–4. All antigen doses were formulated in 0.5 mL AS01B.
(B and C) Median and individual anti-RH5_FL serum total IgG responses 14 days after two vaccinations (Vacs; day 42, B) and after three Vacs (day 70 or
day 196, C). Both datasets were analyzed separately by Kruskal-Wallis test with Dunn’s multiple comparisons test; **p < 0.01. Historical data for the
VV-RH5 vaccine11 were not included in the analysis and are shown for comparison only.
(D) In vitroGIA of purified IgG assessed at 10 mg/mL against 3D7 clone P. falciparum parasites. Individual data and medians are shown for each group at
the stated time-point; pooled sera were used for each group at baseline (day 0). Historical data for VV-RH5 were included as before.
(E) Dilution series of purified IgG for all group 1–4 samples starting from 10 mg/mL.
(F) Relationship between GIA data from the dilution series shown in (E) and concentration of anti-RH5_FL purified IgG used in the assay as measured by
ELISA. A non-linear regression curve is shown for all samples combined (solid line, r2 = 0.96, n = 279). The EC50 (concentration of anti-RH5_FL polyclonal
IgG that gives 50% GIA, dashed line) was calculated.
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OPEN ACCESSClinical Advancesbiomanufacture a soluble protein vaccine, called RH5.1.21 We hypothesized that this
antigen, when presented with a potent adjuvant, could induce significantly higher
levels of anti-RH5_FL antibodies than virus-vectored RH5 (VV-RH5) and therefore
conducted the VAC063 phase I/IIa clinical trial (ClinicalTrials.gov: NCT02927145)
to determine safety, immunogenicity, and efficacy against blood-stage CHMI of
RH5.1 formulated in GlaxoSmithKline’s (GSK) adjuvant system AS01B.RESULTS
The RH5.1/AS01B vaccine is safe and immunogenic
Fifty healthy adult volunteers were enrolled, across three sites in the United
Kingdom, into the phase Ia arm of the VAC063 clinical trial, which assessed the
RH5.1/AS01B vaccine in an open-label, dose-escalation study (Figure 1A and S1).
Three immunizations at monthly intervals with 2, 10, or 50 mg RH5.1 in 0.5 mL
AS01B (groups 1, 2, and 4) were compared with a delayed fractional dosing (DFx)
regimen, where two monthly immunizations of 50 mg RH5.1 were followed by a third
immunization at one-fifth dose (10 mg RH5.1) in 0.5 mL AS01B and delayed to
6 months after the first immunization (group 3). Forty-seven of 50 (94%) volunteers
received all scheduled vaccinations, and 44 completed follow-ups.
All vaccinations in groups 1–4 were well tolerated (Figure S2, Data S1A and S1B), and
no safety concerns arose during the trial period. The reactogenicity of the vaccine
was similar to that seen in previous malaria vaccine trials using the same adjuvantMed 2, 701–719, June 11, 2021 703
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associated with a higher grading of systemic adverse events (AEs) and local redness
(STAR Methods, safety analysis). A single occurrence of scalp psoriasis in one group-
3 volunteer was regraded retrospectively as a suspected unexpected serious
adverse reaction (SUSAR) on the basis of (1) protocol-specified AEs of special inter-
est for the AS01B adjuvant and (2) temporal onset 1 month after the second vaccina-
tion, making a causal relationship ‘‘possible’’ despite being unlikely clinically.
The anti-RH5 total IgG serum antibody concentration (in micrograms per milliliter)
was assessed over time by ELISA against RH5_FL recombinant protein. Two priming
immunizations induced antigen-specific IgG responses in all volunteers, with a clear
dose response on day 42 (Figure 1B). By 2 weeks after the third monthly immuniza-
tion (day 70), responses had equalized across the doses, with median (range) anti-
body levels of 91 (29–219) mg/mL in groups 1, 2, and 4 combined (n = 33). Two weeks
after the final boost in the DFx regimen (day 196), responses trended higher, with
median levels of 118 (45–314) mg/mL (n = 12) in group 3 (Figure 1C). Following
each of the two booster immunizations, a burst of antibody-secreting cells (ASCs)
was measured in the peripheral blood by ELISPOT; these were largely comparable
across the vaccine doses and regimens (Figure S3A). Similar comparability was
seen for interferon g (IFN-g) T cell responses in peripheral blood mononuclear cells
(PBMCs), as measured by ex vivo ELISPOT and flow cytometry, 2 weeks after the
third immunization (Figures S3B–S3D). In comparison with the previously reported
first-generation VV-RH5 vaccine,11 the serum IgG concentrations induced by
RH5.1/AS01B were 10-fold higher, with the opposite trend observed for IFN-g
T cell responses (Figures 1C and S3B). We also assessed serum antibody isotypes
and subclasses by ELISA. Here, the anti-RH5_FL response was mainly composed
of IgG1, IgG3, IgA, and IgM with little detectable IgG2 or IgG4 (Figure S4A), and
this profile was consistent over time and vaccine dose/regimen.
To assess functional antibody activity, sera were analyzed by the GIA Assay Refer-
ence Center at the NIH. IgG was purified from each sample prior to testing against
3D7 clone P. falciparum parasites at a starting concentration of 10 mg/mL total IgG
and in the absence of complement. Pooled samples from groups 1–4 prior to vacci-
nation (day 0) did not demonstrate any GIA above baseline. Samples from group 1–4
volunteers taken 2 weeks after the final immunization showed in vitro GIA, with
median levels ranging between 70%–75% across all four groups (Figure 1D)—
the highest levels of GIA reported in this assay following human vaccina-
tion.11,18,23–25 We confirmed that GIA decreased as purified IgG was diluted in
the assay (Figure 1E). GIA was also related to RH5_FL-specific IgG concentration
(Figure 1F), as seen previously for this antigen following VV-RH5 immunization,11
as well as following human immunization with other antigens, such as MSP1 and
AMA1.16,18,23,24 For RH5.1/AS01B, the concentration of RH5_FL-specific polyclonal
IgG required to give 50% GIA (EC50) was 34 mg/mL (95% confidence interval [CI],
33–36); this ‘‘quality’’ readout of vaccine-induced IgG was identical across the
different dosing groups and regimens.
The DFx regimen improves antibody response longevity
All volunteerswere followedup for 6monthsafter thefinal immunization, atwhichpoint it
becameapparent that the longevity of the anti-RH5_FL IgGantibody responsewas strik-
ingly different following the DFx regimen (group 3) (Figures 2A and S4B). We therefore
invited all volunteers who completed follow-up to return for a ‘‘late bleed’’ (approxi-
mately 1.5–2.5 years after their final vaccination), of whom 30 of 44 (68%) consented.
Serum IgG responses at this late time point were significantly and 10-fold higher in704 Med 2, 701–719, June 11, 2021
Figure 2. Assessment of the DFx regimen
(A) Median anti-RH5_FL serum total IgG responses for groups 1–4 over time. Individual responses are shown in Figure S4B.
(B) Median and individual anti-RH5_FL serum total IgG responses at the time of the late bleed. Statistical analysis was performed using a Mann-Whitney
test, ****p < 0.0001.
(C) Avidity of serum total IgG responses 14 days after three immunizations (day 70 or day 196) was assessed by NaSCN displacement RH5_FL ELISA and
is reported as the molar concentration of NaSCN required to reduce the starting optical density (OD) in the ELISA by 50% (IC50). Individual responses
over time are shown in Figure S4C. Historical data for the VV-RH5 vaccine11 are shown for comparison. Kruskal-Wallis test with Dunn’s multiple
comparison test, ***p < 0.001 for group 3 versus groups 1, 2, and 4.
(D) Estimated proportion of antibodies generated from LLPCs; for group 3, it was possible to provide separate estimates of the proportion following the
first and second doses (purple) and following the third dose (pink). The long-lived response following the third dose in group 3 is significantly greater
than in other groups; ****p < 1 3 106 in all cases by one-sided t test.
(E) Anti-RH5_FL antibody levels at peak and 1 and 4 years following the third vaccine dose. Peak antibody levels are based on the maximum measured
values (day 70 or day 84 for groups 1, 2, and 4 and on day 196 or day 210 for group 3). Antibody levels at 1 and 4 years are based on model estimates and
are presented with 95% CI.
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IgGresponsewas50 (29–140)mg/mL (n=7), in contrast to themonthlydosing regimenof
groups1,2, and4,where the responsewas4 (0.9–13)mg/mL (n=23) (Figure2B). Theanti-
RH5_FL serum IgG antibodies induced by the DFx regimen also showed significantly
higher avidity (as measured by a sodium thiocyanate [NaSCN] displacement ELISA)
compared with antibodies induced by the monthly dosing regimen or viral vectors (Fig-
ure 2C). Notably, the substantial increase in IgG avidity in the DFx group was coincident
with administration of the delayed fractional third immunization and was maintained
thereafter (Figure S4C), whereas avidity in the other groups did not change over time.
We observed no association between the magnitude of the RH5-specific IFN-g T cell
response and the improved maintenance and avidity of the serum IgG responseMed 2, 701–719, June 11, 2021 705
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decreased significantly from day 56 to the time of the delayed third immunization
(day 182), consistent with a natural contraction of these responses over time (Fig-
ure S5A). These responses were of a similar magnitude across the groups and regi-
mens 2 weeks after the final boost (Figure S3B) and still detectable 2 years later in
the memory phase at the time of the late bleed (Figure S5B). More detailed pheno-
typing of the peripheral anti-RH5.1 specific CD4+ T follicular helper (Tfh) cell popu-
lation, induced 2 weeks after the final boost, also revealed no difference between
monthly vaccine dosing versus the DFx regimen (Figures S5C and S5D). However,
we did note that the proportion of Tfh2 cells within the RH5.1-specific Tfh cell pop-
ulation, the subset regarded as the best at providing B cell help during generation of
humoral responses,26 was significantly greater in the delayed fractional dose vacci-
nees (Figure S5E). This suggested a possible qualitative improvement in the Tfh cell
response when using the DFx regimen as opposed to monthly dosing, even when
the magnitude of the total Tfh cell response is comparable. Given these observa-
tions relating to Tfh2 cells, we hypothesized that the DFx regimen could favor induc-
tion of a greater proportion of long-lived plasma B cells (LLPCs) over short-lived
plasma B cells compared with the monthly dosing regimen, leading to improved
maintenance of the anti-RH5_FL serum IgG response over time. To address this,
we undertook a modeling analysis of the serum IgG kinetics (Data S2A). This re-
vealed that the estimated proportion of antibody generated by vaccine-induced
LLPCs was significantly higher following the delayed fractional vaccine dose in group
3 (Figure 2D). A key factor driving the improved longevity of the vaccine-induced
antibody response was thus an 2-fold quantitative increase in the proportion of
antibody generated by the LLPC population. Moreover, modeling of the antibody
response suggested that the improved longevity seen with the DFx regimen would
be maintained up to 4 years (Figure 2E).
Vaccinated and challenged volunteers show inhibition of parasite growth
in vivo
At the time of proceeding to the phase IIa arm of the VAC063 clinical trial, immuno-
genicity data were only available for groups 1, 2, and 4. Given that, following three
monthly immunizations, no substantial differences were observed across the three
doses of RH5.1, we elected to proceed with the 10-mg dose in the challenge study
(called VAC063A). A new cohort of 17 volunteers (group 5) was recruited and vacci-
nated three times at monthly intervals with 10 mg RH5.1 formulated in 0.5 mL AS01B
(Figure 3A and S6), and these volunteers showed an AE profile comparable with that
seen previously with the identical regimen in group 2 (Figures S7 and S2). Three vac-
cinees withdrew during the immunization phase; thus, 14 of these volunteers, along
with 15 unvaccinated infectivity control individuals (group 6), subsequently under-
went primary blood-stage CHMI with 3D7 clone P. falciparum parasites 14 days after
the final immunization (day 70), using an established protocol18 (Figure S6).
All volunteers developed blood-stage parasitemia following CHMI and were subse-
quently drug treated according to a diagnostic algorithm based on patency by thick-
film microscopy and/or pre-defined thresholds of parasites per mL (p/mL) blood by
quantitative PCR (qPCR) and/or symptoms. The protocol pre-specified primary anal-
ysis for vaccine efficacy was comparison of the parasite multiplication rate (PMR) be-
tween the two groups. The PMR for each volunteer was calculated using a protocol
pre-specified linear model fitted to log10-transformed qPCR data
27 (Figures 3B and
S8A; Data S1C). This analysis showed a significant reduction (p = 0.031) in the mean
PMR between the two groups (Figure 3C), with a group 6 (infectivity control individ-
uals) mean of 9.75 (95% CI, 8.39–11.11; standard deviation [SD] = 2.46) and a group706 Med 2, 701–719, June 11, 2021
Figure 3. Results of primary and secondary blood-stage CHMI
(A) Timing of immunizations, CHMIs, and follow-up in groups 5–9. All antigen doses were formulated in 0.5 mL AS01B.
(B) qPCR data for the VAC063A phase IIa study; group 5 (n = 14) and group 6 (n = 15). Median parasitemia is shown over time for each group. The lower
limit of quantification is indicated by the dotted line at 20 p/mL; values below this level are plotted for information only. Time = days after blood-stage
CHMI.
(C) Primary efficacy endpoint analysis of PMR, showing each individual plus the mean. Both datasets are normally distributed (D’Agostino-Pearson test);
*p = 0.031 using two-tailed t test with Welch’s correction for non-equal variances (F test; p = 0.008).
(D) Kaplan-Meier plot of time to diagnosis in days for the VAC063A study. Median time to patent parasitemia was 9.5 days for control individuals and
10.5 days for vaccinees. Secondary pre-specified efficacy analysis in the protocol compared time to diagnosis between the groups; p = 0.01, Mann-
Whitney test.
(E) Post hoc analysis combining the VAC063A dataset with the AMA1/AS01B trial (VAC054) data
18. Mean PMR G 95% CI is shown for control individuals
(n = 15 from VAC063A and n = 15 from VAC054), AMA1 vaccinees (n = 12 from VAC054), and RH5 vaccinees (n = 14 from VAC063A). *p < 0.05 for RH5
versus AMA1 and control individuals, using one-way ANOVA with Bonferroni correction for multiple comparisons.
(F) qPCR data for the VAC063B phase IIa study shown as in (B); group 7 (n = 9), group 8 (n = 8), and group 9 (n = 6).
(G) Secondary efficacy endpoint analysis of PMR, showing each individual, plus the median. *p = 0.022; Kruskal-Wallis test with Dunn’s multiple
comparison test.
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OPEN ACCESSClinical Advances5 (vaccinees) mean of 8.12 (95% CI, 7.47–8.77; SD = 1.13). This reduction in PMR by
20% (from10-fold per 48 h in control individuals to8-fold in vaccinees) was also
evident by significantly lower parasitemia at individual time points (Figure S8B) and
would also predict an approximately 1-day delay to diagnosis at a threshold of
10,000 p/mL, as was indeed observed by the protocol pre-specified secondary effi-
cacy analysis (Figure 3D). A post hoc analysis combined these PMR data with those
from our previous VAC054 phase I/IIa clinical trial of the FMP2.1 AMA1/AS01B pro-
tein/adjuvant vaccine that was assessed for efficacy in an identical manner.18 This
combined analysis of 30 controls, 12 AMA1 vaccinees, and 14 RH5 vaccinees
showed a significantly lower mean PMR in RH5 vaccinees compared with AMA1 vac-
cinees and the control individuals (Figures 3E and S8C). These data provide the first
evidence of a significant in vivo effect of a malaria vaccine candidate on blood-stage
parasite growth in humans following CHMI.
In light of these data, we invited group 5 and 6 volunteers to return for a re-challenge
study (VAC063B). Eight control individuals consented (now referred to as group 8),
along with nine vaccinees who were re-boosted with a single 10-mg dose RH5.1Med 2, 701–719, June 11, 2021 707
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(now referred to as group 7). The AE profile of this delayed fourth RH5.1 immuniza-
tion was comparable with the second immunization (Figure S7). Fourteen days after
vaccinating group 7, all volunteers underwent secondary blood-stage CHMI, exactly
as before, alongside six new malaria-naive primary CHMI control volunteers (group
9) (Figures 3A and S6). All volunteers developed blood-stage parasitemia following
CHMI and were drug treated according to a diagnostic algorithm based on qPCR
and/or symptoms, except for one group 8 volunteer who requested treatment on
day of challenge (dC)+20 (Figures 3F, S8D, and S8E; Data S1D). qPCR-derived
PMR again constituted the efficacy endpoint, and data were analyzed for all volun-
teers. The new group 9 primary controls showed parasite growth dynamics highly
similar to the VAC063A study control individuals, with a mean PMR of 11.22 (95%
CI, 9.20–13.23; SD = 1.92). Notably, one of the eight unvaccinated control individ-
uals (group 8) undergoing secondary CHMI showed a dramatically reduced PMR
(1.45-fold growth/48 h), with parasites not detectable by qPCR until dC+19. A sec-
ond group-8 volunteer also showed evidence of reduced growth, but the remaining
six volunteers in group 8 had PMRs in line with the primary control individuals (group
9). In contrast, 8 of 9 RH5 vaccinees showed PMRs that were lower than any of the
primary controls, with an overall significantly reduced mean PMR of 7.62 (95% CI,
6.51–8.73; SD = 1.44) in comparison with group 9 (Figure 3G; adjusted p = 0.022 us-
ing Kruskal-Wallis test with Dunn’s multiple comparisons post hoc test). The
observed PMRs in group 7 and 8 volunteers also correlated with their PMRs from
the primary CHMI (Figure S8F). These data confirm the ability of RH5 vaccination
to significantly affect in vivo blood-stage parasite growth in humans.Anti-RH5 antibody responses can boost following repeat vaccination after
CHMI
We next assessed the anti-RH5_FL serum antibody response over the course of both
CHMI studies (Figure 4A). The levels induced in group 5 vaccinees by dC-1 (prior to
the first CHMI) were highly similar to those measured in the original group 2 vacci-
nees on day 70, confirming comparability across these replication cohorts (Figures
4B and S9A). Also, despite CHMI and as seen for group 2, the peak responses in
group 5 soon waned, resulting in significantly lower responses by 28 days after
CHMI (dC+28) (Figure 4A). The fourth RH5.1/AS01B immunization nevertheless re-
boosted these antibodies, which trended toward higher levels by dC-1 for the
secondary CHMI (Figure 4B). Intriguingly, after the second CHMI, there was no sig-
nificant change in anti-RH5_FL serum IgG levels between dC-1 and dC+28 for the
group 7 vaccinees. These responses were significantly higher than when measured
in the same individuals 28 days after their primary infection (Figures 4A and 4C). A
possible explanation is that they were naturally boosted or maintained by the sec-
ond CHMI. However, there was no evidence of natural boosting in the primary
CHMI (given comparable antibody levels in groups 2 and 5 regardless of CHMI,
approximately 3 months after their last immunization) (Figure 4D). There was also
no detectable induction of de novo anti-RH5_FL serum IgG responses in control vol-
unteers after one or two rounds of CHMI (Figure 4C), consistent with RH5’s known
poor immunogenicity in the context of natural malaria infection9–12,28 and primary
CHMI.29 Moreover, the anti-RH5_FL serum IgG in group 7 was also better main-
tained over the next 1–2 years (Figures 4D and 4E), closely mirroring our previous
observations in group 3 using the DFx regimen. These data therefore suggest that
the fourth delayed (but non-fractional) immunization in group 7 led to improved
longevity of the anti-RH5_FL serum IgG response. Consistent with this, the anti-
RH5_FL IgG responses in group 5/7 volunteers also showed a significant increase708 Med 2, 701–719, June 11, 2021
Figure 4. Antibody responses after CHMI and the fourth booster immunization
(A) Median and individual anti-RH5_FL serum total IgG responses shown for groups 5 and 7 over time (note that a subset of group 5 vaccinees became
group 7; Figure S6). Gray shading indicates periods of CHMI, and arrows indicate Vacs. The legend indicates the sequence of 10-mg RH5.1/AS01B Vacs
as well as the first and second CHMIs, as relevant to each group.
(B–E) Individual and median responses are shown for the indicated groups and time points. dC, day of challenge. *p < 0.05, **p < 0.01; Wilcoxon
matched-pairs signed-rank test in (C) and (D). *p < 0.05, Mann-Whitney test in (E).
(F) Avidity of serum total IgG responses in groups 5 and 7 at the indicated time points was assessed by NaSCN displacement RH5_FL ELISA. *p < 0.05,
**p < 0.01; Friedman test for paired samples with Dunn’s multiple comparisons test.
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previously with the DFx regimen (Figure 2C).
In vitro growth inhibition correlates with in vivo growth inhibition
We next assessed functional in vitro GIA for groups 5–9 as done previously, using puri-
fied IgG from the dC-1 time point at a starting concentration of 10mg/mL. There was no
GIA above baseline prior to primary or secondary challenge of any control volunteers, in
contrast to high levels in groups 5 and 7 (Figure 5A). Titration of IgG again showed that
GIA was related to RH5_FL-specific IgG concentration, with an antigen-specific EC50 of
35 mg/mL (95% CI, 33–37), identical to that observed previously in groups 1–4 (Figure
5B). To assess the relationship between in vitro GIA and in vivo outcome following
CHMI, we calculated the in vivo growth inhibition (IVGI) for each vaccinated volunteer
as the percentage of reduction in the PMR in each individual relative to the mean in
themalaria-naive control group. In this post hoc analysis, we included all vaccinated vol-
unteers assessed over three blood-stage CHMI studies (group 5, group 7, and our pre-
viously reported AMA1/AS01B vaccine trial
18). Data from previous Aotus monkey
P. falciparum challenge studies suggested that levels of in vitro GIA of more than 60%
at 2.5 mg/mL purified IgG are associated with a protective outcome following blood-
stage vaccination.17,30 Consistent with this, the median levels of IVGI in each group
increased as their in vitroGIA increasedwhen using 2.5mg/mL purified IgG in the assay,
although no individual measured more than 60% (Figure 5C). Moreover, there was a
highly significant correlation between the in vitro assay of GIA and IVGI (Figure 5D),Med 2, 701–719, June 11, 2021 709
Figure 5. Analysis of in vitro GIA versus IVGI
(A) In vitro GIA of purified IgG assessed at 10 mg/mL against 3D7 clone P. falciparum parasites.
Individual data and medians are shown for each group (Figure 3A) at the stated time points.
(B) Relationship between GIA and concentration of anti-RH5_FL purified IgG used in the assay,
as measured by ELISA. A non-linear regression curve is shown for all samples combined (solid line,
r2 = 0.97, n = 180). The EC50 (dashed line) was calculated.
(C) In vitro GIA as in (A), using purified IgG assessed at 2.5 mg/mL. Historical data from the AMA1/
AS01B (VAC054) trial
18 are included. The median percent IVGI observed in each group following
blood-stage CHMI is indicated below the graph. The red dashed line at 60% GIA indicates the
threshold level required for protection in Aotus monkeys.17,30 *p < 0.05, **p < 0.01; Kruskal-Wallis
test with Dunn’s multiple comparisons test.
(D) Correlation of % IVGI observed in each individual following blood-stage CHMI versus their
individual in vitro GIA measured at dC1 using 2.5 mg/mL purified IgG. Spearman’s rank
correlation coefficient and p value are shown; n = 35. Colored symbols are the same as those used in
(C) for AMA1, group 5 (G5), and G7.
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ure S9B). Given that the GIA assay uses a normalized concentration of purified IgG,
we also related these results to each individual’s serum IgG concentration (Figures
S9C and S9D), and the correlation remained highly significant (Figure S9E). These
data provide the first strong evidence that the in vitro GIA assay can correlate with
outcome against blood-stage P. falciparum CHMI in vaccinated humans; this is highly
consistent with previous non-human primate studies that also assessed MSP1, AMA1,
or RH5 vaccine efficacy against blood-stage malaria challenge.17,30,31
The anti-RH5 plasma IgA1 response is associated with delayed time to
diagnosis
Despite observing a significant correlation between in vitro GIA and IVGI after
blood-stage CHMI, we hypothesized that the vaccine-induced polyclonal anti-RH5710 Med 2, 701–719, June 11, 2021
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measured in the standardized GIA assay but still relevant to mediating protection
against merozoite invasion. The GIA assay provides a neutralization-type readout us-
ing purified IgG lacking immune cells, complement, and other vaccine-induced anti-
body isotypes/subclasses. To address this limitation of the GIA assay, we also under-
took an exploratory analysis using a systems serology approach.32,33 Here we
initially measured a diverse array of antibody features and functions prior to using
these datasets for computational modeling. Our aim was to decipher the most
important antibody feature sets that are associated with reduced parasite growth
in vivo, identifying key immune parameters for future experimental vaccine testing.
Initially, we sought to (1) quantify the post-vaccination plasma levels of RH5-specific
antibodies of each major isotype and subclass; (2) evaluate the capacity of anti-RH5
antibody to bind Fc receptors (FcRs) and activate natural killer (NK) cells, neutrophils,
monocytes, and the complement cascade; and (3) characterize the glycosylation
profile of the anti-RH5 IgG Fc domains, which is known to influence these Fc-medi-
ated functions.34 We then performed computational analyses with these in vitro
assay datasets for RH5 vaccinee (groups 5 and 7) dC-1 plasma samples and the
DOD and IVGI efficacy measures (Figures 6A and S10A; Data S2B). Correlation anal-
ysis confirmed a positive relationship between the DOD and IVGI efficacy measures
(as would be expected) and identified a strong positive correlation between anti-
body-dependent neutrophil phagocytosis (ADNP) and IVGI (Figures 6A and 6B).
Computational analysis was subsequently able to generate a model that could pre-
dict values within a cross-validation framework that were consistently and signifi-
cantly correlated (p = 0.011) with the DOD efficacy readout data measured in the
trial (Figure 6C). The same modeling analysis using the IVGI efficacy readout but
marginally missed significance (p = 0.053) (Figures S10B–S10E).
We therefore proceeded to identify the set of in vitro systems serology features that
are most important for the DOD model. These are shown in decreasing order of
importance (Figure 6D), along with correlations between DOD and the top seven
features (Figure 6E): magnitude of the anti-RH5 IgA1 response, IgA1:IgA2 ratio,
magnitude of anti-RH5 IgA2, binding of RH5-specific antibody to FcRn, anti-RH5
antibody binding to FcaRI, proportion of RH5-specific IgG Fc glycans that are fuco-
sylated 2-galactose with bisecting N-acetylglucosamine (G2FB), and magnitude of
anti-RH5 IgG1. Although the FcRn and IgG1 readouts are highly correlated with
many other features, the IgA readouts, FcaRI binding, and G2FB glycan results
show greater independent importance (Figure 6F). These data therefore indicate a
relationship between an increased anti-RH5 IgA1 response and delayed time to
diagnosis and highlight this response for future investigation.DISCUSSION
Development of an effective blood-stage vaccine against P. falciparum has proved
challenging. Historical protein-in-adjuvant vaccine candidates against the MSP1,
AMA1, or MSP3-GLURP antigens have shown no efficacy,35,36 strain-specific effi-
cacy,37 or low-level efficacy38 in phase IIb field trials in African children or infants.
The two vaccines to report efficacy signals in the field underwent retrospective
testing by CHMI in adults, but no differences were observed between vaccinees
and control individuals,18,39 suggesting that the challenge model may pose a higher
bar for efficacy even when using vaccine-homologous parasites. Consistent with this,
no other blood-stage P. falciparum subunit vaccine candidate has significantly
reduced the in vivo PMR (in vaccinees compared with control individuals) followingMed 2, 701–719, June 11, 2021 711
Figure 6. Systems serology analysis of CHMI outcome in RH5 vaccinees
(A) Correlation heatmap showing the Spearman rank correlation coefficients (rS) between Fc functions and titers as well as the rank correlation of the
features to the CHMI readouts of DOD and IVGI. *q < 0.1, **q < 0.01 (Benjamini-Hochberg procedure for multiple testing correction; the correction was
done within the groups of comparison; 54 comparisons for Fc functions/titer, 40 for features/DOD, and 40 for features/IVGI).
(B) Scatterplot to show the relationship between ADNP score and IVGI. Each color corresponds to one volunteer, and the shape indicates the group:
G5 (n = 13) or G7 (n = 7).
(C) Prediction for the random forest regression model plotted against the data for DOD. The model was obtained using leave-one-volunteer-out cross-
validation. The Pearson correlation coefficient (rP) and p value are shown.
(D) The antibody features in the predictive model for DOD are ranked according to how often they were chosen for 100 repetitions of recursive feature
elimination (RFE) in the leave-one-volunteer-out cross-validation.
(E) Graphs showing DOD versus systems serology assay data for the seven antibody features that were chosen in more than 10% of the elimination
procedures (D).
(F) The co-correlates network shows the pairwise correlation of features. The nodes correspond to features and the edges to Spearman rank correlations
between the features. Only significant correlations (Benjamini-Hochberg q < 0.05) between features that are selected in more than 10% of the RFE
procedures and all other features are shown. G2FB Fc glycan, fucosylated 2-galactose with bisecting N-acetylglucosamine.
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out an adjuvant effect).25,40–42 Reduced PMRs (as measured by qPCR and compared
with malaria-naive adults) are nevertheless observed in semi-immune African adults
following natural infection43 or CHMI.44,45 Consequently, our data with RH5.1/
AS01B provide the first demonstration of a significant in vivo effect on PMR following
vaccination and primary blood-stage CHMI, defining a milestone for the blood-
stagemalaria vaccine field. These findings were confirmedwhen a greater significant
effect on in vivo PMR was also seen in a subset of nine vaccinees who received
a fourth booster vaccination followed by secondary CHMI. However, the overall712 Med 2, 701–719, June 11, 2021
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diagnosis, as would be predicted when reducing the growth rate from an average
of 10-fold to 7- to 8-fold per 48 h.3 Improved next-generation vaccine immuno-
gens and/or formulations targeting RH5 or its invasion complex are now required to
achieve protection via more substantial reductions in PMR.
We also identified the in vitro assay of GIA as a highly significant predictor of IVGI,
following a post hoc analysis of data across three blood-stage P. falciparum CHMI
studies, using vaccines targeting RH5 or AMA1. This quantitative association was
nearly identical to that we reported previously following vaccination and
P. falciparum challenge of Aotusmonkeys.17 More recently, we confirmed this asso-
ciation as a mechanistic correlate in Aotus monkeys; i.e., one that can cause in vivo
protection via passive transfer of a GIA-positive, RH5-specific IgG monoclonal anti-
body (mAb),46 with similar results observed in humanized mice.47 Full protection of
Aotus monkeys required a serological threshold level of GIA,17,30 which we ap-
proached in this trial of adults in the United Kingdom but did not exceed. Nonethe-
less, our analysis of RH5.1/AS01B now provides defined benchmark levels of GIA and
IVGI in humans; these can guide interpretation of future clinical trials of populations
living in malaria-endemic areas as well as endeavors to develop improved RH5-
based vaccines.
Our systems serology analysis also identified other antibody feature sets, most
frequently including the plasma anti-RH5 IgA1 response, that are associated with
challenge outcome. These data provide important evidence to support the notion
that ‘‘neutralization’’ of erythrocyte invasion by IgG (as measured by the GIA assay)
may not be the only relevant component of functional vaccine-induced immunity
against the merozoite. The relationship between ADNP and IVGI implies that the
role of IgA1 could be related to activation of neutrophils, the most abundant im-
mune cells in the blood and, therefore, intuitively the most likely cells to be in close
proximity to a rapidly invadingmerozoite. Previous work has reported that antibody-
dependent respiratory burst (ADRB) activity from neutrophils can be associated with
clinical immunity to malaria.48 Further studies and novel assay development are now
required to interrogate mechanism-of-action hypotheses for vaccine-induced RH5-
specific IgA1, replicate these findings, and synthesize the relative contributions of
different antibody effector functions against the blood-stage merozoite.
Our data also confirm the quantitative challenge of achieving high-level antibody-
mediated protection against the merozoite. Protection of Aotus monkeys necessi-
tated more than 300 mg/mL anti-RH5 IgG or more than 60% GIA using 2.5 mg/mL
purified IgG in the assay,17 and, although we approached these immunological
thresholds in humans, a minimum 3-fold quantitative improvement is still required
to exceed them. Nevertheless, the relationship reported here in humans between
in vitro GIA and IVGI following CHMI is highly similar to that we reported previously
for Aotus monkeys vaccinated with RH5 and then challenged with blood-stage
P. falciparum,17 suggesting a strong degree of comparability across these two
species.
Addressing the challenge of how to further improve the quantity and/or quality of
the vaccine-induced anti-merozoite antibody response is now of strategic impor-
tance. First, evidence from clinical trials of pre-erythrocytic malaria subunit vaccine
candidates suggests that substantially higher antibody responses (in the range of
5- to 10-fold) are observed in the target population (African infants) compared
with malaria-naive adults.49–51 Consequently the first phase Ib data of the VV-RH5Med 2, 701–719, June 11, 2021 713
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Trials.gov: NCT03435874 and NCT04318002). These will provide important insight
regarding whether the efficacy of RH5-based vaccines is potentially underestimated
by CHMI in adults in the United Kingdom because of relatively lower levels of anti-
body response. A second strategy to improve RH5-based vaccines would be to
incorporate the other, more recently described antigens CyRPA and RIPR, which
associate with RH5 to form a heterotrimeric protein complex; like RH5, both of these
antigens are highly conserved and essential and can induce high levels of growth-
inhibitory antibodies following vaccination of animals.6,52 Finally, rational improve-
ments of the design and delivery of the RH5 immunogen should also be explored.
Strategies to achieve substantial improvements in the quantity and/or quality of vac-
cine-induced polyclonal anti-RH5 IgG would include analysis of vaccine-induced
anti-RH5 human mAbs53 to inform structure-based vaccine design54 coupled with
improved delivery of novel RH5 immunogen arrays on virus-like particles.55 In-depth
analysis of the RH5 antibody epitope specificities induced by the RH5.1/AS01B vac-
cine, linked to structure and functional outcome, will be essential to guide these
future approaches to improve the vaccine by rational design.
However, even when protective levels of antibody are achieved, these levels of func-
tional antibody must also be maintained if they are to provide a useful duration of
immunity. Our CHMI data suggest that RH5-based vaccines cannot rely on ‘‘natural
boosting’’ followingmalaria exposure, fully consistent with the poor immunogenicity
of RH5 in the context of malaria infection. Nevertheless, given the potential of ma-
laria infection to have immunomodulatory effects on B cell responses,56 our finding
that CHMI did not negatively affect vaccine-induced antibody titers or the ability to
boost existing anti-RH5 IgG responses is encouraging for future vaccine use in ma-
laria-endemic areas. Furthermore, our assessment of the DFx regimen builds on the
experiences of the RTS,S/AS01 vaccine,57 aligns with emerging strategies for sea-
sonal malaria vaccination,58 and offers significant promise for induction of more
durable malaria immunity. Although not definitive, our data from the delayed fourth
RH5.1/AS01B booster vaccination in the vaccinated and challenged cohort also sug-
gest that the delay (as opposed to dose fractionation) is the major contributor to this
effect. This is also consistent with our observations that RH5.1 vaccine doses ranging
from 2–50 mg showed comparable immunogenicity, albeit after monthly as opposed
to DFx dosing.
Regardless, the DFx regimen showed higher average anti-RH5 IgG responses at the
peak as well as significantly improved anti-RH5 IgG avidity and longevity, with
modeling of the antibody kinetics at 4 years suggesting that an10-fold quantitative
improvement would be maintained (compared with the monthly dosing regimen).
Further quantitative and qualitative analyses of the underlying cellular responses
are now warranted in the DFx regimen vaccinees, given that our data indicate (1)
that an increased proportion of the antibody response is generated by the LLPC
population and (2) a RH5-specific Tfh2 cell skew, again similar to a recent report
for RTS,S/AS01.59 Notably, improved anti-RH5 IgG avidity did not affect in vitro
GIA; however, this observation is consistent with recent human anti-RH5 mAb
data indicating that speed of binding (i.e., antibody on-rate) is a key determinant
of GIA potency as opposed to off-rate/overall affinity or strength of binding.53
Nevertheless, improved antibody avidity is associated with increased anti-sporo-
zoite vaccine efficacy against CHMI,57 suggesting that regimen optimization could
add significant value to ongoing efforts to improve other malaria subunit vaccines.
Our data also pose a wider challenge to the traditional dosing and boosting regi-
mens used for human vaccine development. Substantial gains in vaccine-induced714 Med 2, 701–719, June 11, 2021
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mization of dose and delivery regimen.
Limitations of study
Our study has certain limitations. First, although powered for a certain effect size in
the primary CHMI, the trial still has a relatively small sample size. This is fairly com-
mon for early-phase malaria vaccine clinical trials that seek to demonstrate proof of
concept for vaccine safety, dosing, regimen, and/or efficacy using the CHMI model.
Also, some analyses, including secondary CHMI and late bleed to assess antibody
response longevity after 1.5–2.5 years, were amended into the trial protocol in
light of promising data arising in the original part of the study. This relied on volun-
teers being able and willing to return to the trial and led to an inevitable reduction in
sample size. Second, although our analysis of efficacy in the primary CHMI study was
pre-specified, our investigation of immune responses that were associated with
in vivo outcome following CHMI was post hoc and exploratory. Our conclusions
could therefore be strengthened in the future by a replication cohort with larger
sample size to assess vaccine efficacy, alongside pre-specified analyses of the immu-
nological responses identified here that were associated with CHMI outcome mea-
sures. Third, our systems serology assays to measure antibody function utilized re-
combinant RH5 protein as opposed to merozoites; although technically
challenging, on-going development of these assays to incorporate whole parasites
should be an improvement. Finally, blood-stage CHMI remains a model to investi-
gate blood-stage vaccine efficacy and was used here in malaria-naive adults in the
United Kingdom. It is ultimately imperative to understand how these observations,
using the CHMI model, relate to efficacy against natural mosquito-borne infection
in African infants, the target population for such a vaccine.
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56. Pérez-Mazliah, D., Ndungu, F.M., Aye, R., and
Langhorne, J. (2020). B-cell memory in malaria:
Myths and realities. Immunol. Rev. 293, 57–69.
57. Regules, J.A., Cicatelli, S.B., Bennett, J.W.,
Paolino, K.M., Twomey, P.S., Moon, J.E.,
Kathcart, A.K., Hauns, K.D., Komisar, J.L.,
Qabar, A.N., et al. (2016). Fractional Third and
Fourth Dose of RTS,S/AS01 Malaria Candidate
Vaccine: A Phase 2a Controlled HumanMalaria
Parasite Infection and Immunogenicity Study.
J. Infect. Dis. 214, 762–771.
58. Chandramohan, D., Dicko, A., Zongo, I.,
Sagara, I., Cairns, M., Kuepfer, I., Diarra, M.,
Tapily, A., Issiaka, D., Sanogo, K., et al. (2020).
Seasonal malaria vaccination: protocol of a
phase 3 trial of seasonal vaccination with the
RTS,S/AS01E vaccine, seasonal malariachemoprevention and the combination of
vaccination and chemoprevention. BMJ Open
10, e035433.
59. Pallikkuth, S., Chaudhury, S., Lu, P., Pan, L.,
Jongert, E., Wille-Reece, U., and Pahwa, S.
(2020). A delayed fractionated dose RTS,S
AS01 vaccine regimen mediates protection via
improved T follicular helper and B cell
responses. eLife 9, e51889.
60. Cheng, Q., Lawrence, G., Reed, C., Stowers, A.,
Ranford-Cartwright, L., Creasey, A., Carter, R.,
and Saul, A. (1997). Measurement of
Plasmodium falciparum growth rates in vivo: a
test of malaria vaccines. Am. J. Trop. Med. Hyg.
57, 495–500.
61. Stoute, J.A., Slaoui, M., Heppner, D.G., Momin,
P., Kester, K.E., Desmons, P., Wellde, B.T.,
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Anti-CXCR5-AF700 (clone: RF8B2) BD Biosciences 565191
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Anti-IFN-g-PerCP-Cy5.5 (clone: 42.B3) Life Technologies 45-7319-42
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Pacific Blue anti-huCD66b Biolegend 305112
APC-Cy7 anti-huCD3 Biolegend 300426
BV605 anti-huCD107a Biolegend 328634
PE anti-huIFN-g Biolegend 506507
FITC-conjugated, goat anti-guinea pig





PE-conjugated huIgM Southern Biotech 9020-09
PE-conjugated huIgA1 Southern Biotech (#9130-09),
PE-conjugated huIgA2 Southern Biotech 9140-09
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P. falciparum (clone 3D7) parasitized red blood cells QIMR Berghofer Medical Research Institute, Brisbane 60
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Chemicals, peptides, and recombinant proteins
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Q526 based on 3D7 clone of P. falciparum with
C-terminal E-P-E-A C-tag)
University of Oxford 21
AS01B adjuvant GlaxoSmithKline (GSK) N/A
Dimethyl sulfoxide (DMSO) Sigma D2650
RH5.1 peptides, 20mers overlapping by 10aa NEO Scientific, USA
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Biotinylated RH5 University of Oxford
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FCGR2A avi tag Duke Human Vaccine Institute Protein Production facility N/A
FCGR2B avi tag Duke Human Vaccine Institute Protein Production facility N/A
FCGR3A avi tag Duke Human Vaccine Insitute Protein Production facility N/A
FCGR3B avi tag Duke Human Vaccine Insitute Protein Production facility N/A
Purified human C1q protein Sigma C1740
EZ-Link-NHS-LC-LC-Biotin Pierce A35358
Streptavidin-PE Prozyme PJ31S
Streptavidin coated microspheres New England Biolabs S1420S
IdeZ enzyme New England Biolabs P0770S
PNGase F Applied Biosystems A28404
Bir A Ligase Avidity BirA500
Streptavidin-BB515 BD 564453
Critical commercial assays
QIAGEN DSP DNA Midi Kit QIAGEN 937255
RosetteSep human NK cell enrichment cocktail StemCell 15065
Glycan Assure kit Thermo A28676
TaqMan Universal PCR master mix Applied Biosystems 4440038
Experimental models: Cell lines
RH5.1 production cell line: Drosophila
melanogaster Schneider 2 (S2) cell line
ExpreS2ion Biotechnologies, Denmark 21
THP-1 cells ATCC TIB-202
Experimental models: Organisms/strains





Reverse primer (50 TCAACTACGAACGTTTT
AACTGCAAC 30 )
Applied Biosystems N/A
TaqMan FAM-NFQ-MGB Probe (50 FAM-
AACAATTGGAGGGCAAG-NFQ-MGB 30 )
Applied Biosystems 4316033
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
Parasite or Plasmid DNA qPCR standards University of Oxford N/A
Software and algorithms
ABI StepOne Plus machine with v2.3 software Applied Biosystems 4376598
Gen5 ELISA software v3.04 Biotek, UK N/A
GraphPad Prism version 8.3.1 for Windows GraphPad Software Inc. N/A
FlowJo v10, Treestar Treestar N/A
R notebook (analysis_Rh5.R.md) Data S2
BD FACSDiva8.0 Software BD Biosciences N/A
R version 3.3.3 R foundation for Statistical Computing, Vienna, Austria N/A
Other
ABI StepOne Plus machine Applied Biosystems N/A
Biotek Elx808 reader Biotek N/A
Fortessa X20 flow cytommeter BD Biosciences N/A
QIAsymphony SP robot QIAGEN N/A
ELISPOT counter Autoimmun Diagnostika, Germany N/A
Agilent 1260 HPLC system Agilent, UK N/A
Bio-Monolith Protein G column Agilent N/A
Intellicyt iQue Screener PLUS flow cytometer Intellicyt N/A
ABI 3500xL Genetic Analyzer + software Applied Biosystems N/A
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Lead contact
Further information and requests for resources and reagents should be directed
to and will be fulfilled by the lead contact, Simon Draper (simon.draper@ndm.ox.
ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The published article includes the R notebook (analysis_Rh5.Rmd) for the Systems
Serology analysis (see Data S2B).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
VAC063 Study Design, Subject Details and Study Procedures
RH5.1/AS01B Vaccine. The RH5.1 protein consists of the entire full-length ectodo-
main of the PfRH5 antigen (amino acids E26 – Q526) with the sequence based on
the 3D7 clone of P. falciparum. The vaccine was produced from a stable Drosophila
melanogaster Schneider 2 (S2) cell line, and also contained an N-terminal 18 aa BiP
insect signal peptide (MKLCILLAVVAFVGLSLG) that is cleaved off as the protein is
secreted from the cell, and a C-terminal four amino acid (E-P-E-A) ‘‘C-tag’’ used
for affinity purification.20 The cell line system called ExpreS2 was provided by
ExpreS2ion Biotechnologies in Denmark.19 All four putative N-linked glycosylation
sequons (N-X-S/T) were mutated Thr to Ala – as performed for a previous PfRH5 pro-
tein vaccine produced in mammalian HEK293 cells and tested in rabbits9 and Aotus
monkeys.17
RH5.1 was manufactured under Good Manufacturing Practice (GMP) by the Clinical
Biomanufacturing Facility (CBF) in Oxford in 2015 and protein vaccine stability was
monitored over time, as previously reported in detail.21 The doses used in this study
were 2 mg, 10 mg and 50 mg (nominal doses as the actual doses may have variede3 Med 2, 701–719.e1–e19, June 11, 2021
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stored at the clinical facilities between 70C and 90C. The adjuvant system
AS01B was provided by GlaxoSmithKline (GSK) and stored as a 0.5 mL extractable
liquid in a mono-dose glass vial at +2 to +8C before use. The RH5.1 protein and
AS01B adjuvant were mixed in the clinic prior to use and injected (within 1 h) intra-
muscularly into the non-dominant deltoid (carried out as per local Standard Oper-
ating Procedures MC031 and VC002).
Study Design and Approvals. VAC063 was a first-in-human, open-label, non-random-
ized, multi-center, dose escalation Phase I/IIa clinical trial evaluating the safety,
immunogenicity and efficacy of the recombinant blood-stage malaria protein
RH5.1 formulated in GSK’s adjuvant system AS01B.21 The study was conducted in
the UK at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Univer-
sity of Oxford (Phase I/IIa), the NIHR Wellcome Trust Clinical Research Facility
(WTCRF) in Southampton (Phase Ia) and Guys and St Thomas’ NIHR Clinical Research
Facility, London (Phase I/IIa). All volunteers recruited were healthy, malaria-naive
adults (males and females) aged between 18 and 45 years. Vaccine efficacy was as-
sessed using blood-stage controlled human malaria infection (CHMI) by injection
of parasitized red blood cells,18 as described below. Blood-stage CHMI and
follow-up for all challenged volunteers took place at the CCVTM at the University
of Oxford. There were nine study groups across two phases of the trial, with a total
of 88 volunteers enrolled (33 male and 55 female); 50 in Phase Ia, 38 in Phase IIa
(see Figures S1 andS6 for more detail). The trial was registered on ClinicalTrials.
gov (NCT02927145) and was conducted according to the principles of the current
revision of the Declaration of Helsinki 2008 and in full conformity with the ICH guide-
lines for Good Clinical Practice (GCP). All volunteers signed written consent forms,
and consent was checked to ensure volunteers were willing to proceed before
each vaccination and prior to CHMI.
The study received ethical approval from the UK NHS Research Ethics Service
(Oxfordshire Research Ethics Committee A, Ref 16/SC/0345), and was approved
by the UK Medicines and Healthcare products Regulatory Agency (Ref 21584/
0362/001-0011).
The primary objectives of the trial were to i) assess the safety of the RH5.1/AS01B
vaccine in healthy volunteers at different doses; ii) assess the in vitro GIA against
3D7 clone P. falciparum parasites of IgG purified from the serum of vaccinees; and
iii) to establish whether the RH5.1/AS01B vaccine could demonstrate a reduced
parasite multiplication rate (PMR) in vaccinated subjects compared to infectivity con-
trols in a blood-stage CHMI model (PMR being the primary efficacy endpoint). Sec-
ondary objectives were to assess immunogenicity and the durability of any reduction
in PMR after a secondary blood-stage CHMI four months after the primary challenge.
The study was conducted in healthy volunteers aged 18 - 45 and was in two parts
(Figures S1 and S6). The first part was a dose escalation / dose finding study (Phase
Ia), examining the safety and immunogenicity of the vaccine (Groups 1-4, recruited
and vaccinated at the CCVTM,Oxford; Guys and St Thomas’ NIHR CRF, London; and
the NIHR WTCRF, Southampton). Participants in Groups 1, 2, and 4 received three
vaccinations with RH5.1/AS01B at days 0, 28 and 56, with a dose escalation of
RH5.1 from 2 mg (Group 1), to 10 mg (Group 2), to 50 mg (Group 4), each administered
in 0.5 mL AS01B. Participants in Group 3 received the same initial two 50 mg doses of
RH5.1 as Group 4 (in 0.5mL AS01B) but then received a final fractional (one fifth) dose
(10 mg RH5.1) given at day 182 (rather than 50 mg RH5.1 given at day 56 in Group 4).Med 2, 701–719.e1–e19, June 11, 2021 e4
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ments with the DFx regimen when using the pre-erythrocytic malaria vaccine
RTS,S/AS01.57,61 Nominal study vaccination days are reported throughout; a win-
dow period of G 7 days was permitted in the protocol. Volunteers in Groups 1-4
were enrolled between 17 October 2016 and 6 December 2017.
The second part of the study evaluated vaccine efficacy using a blood-stage CHMI
methodology,18 taking forward the optimal vaccine dose (selected from Groups 1,
2 and 4 only) as determined by the Phase Ia. Volunteers for the Phase IIa (Groups 5-
8) were recruited at the CCVTM, Oxford, and at Guy’s and St Thomas’ NIHR CRF,
London and were enrolled between 4 September 2017 and 13 November 2017.
Seventeen volunteers (Group 5) received three successive vaccinations with
10 mg RH5.1 in 0.5 mL AS01B at 0, 28 and 56 days. Fourteen of these vaccinated
volunteers went on to receive an intravenous blood-stage CHMI in parallel with
fifteen unvaccinated malaria-naive infectivity control volunteers (Group 6), and
any efficacy (assessed by a reduction in the PMR) was reported. This arm of the
CHMI study was also termed ‘‘VAC063A.’’ Nine of these fourteen Group 5 vacci-
nees (Group 7) then went on to receive a fourth and final booster vaccination
with RH5.1/AS01 B (again at a dose of 10 mg RH5.1 in 0.5 mL AS01B) approximately
four months after their third vaccination. Two weeks later they were administered a
second homologous intravenous blood-stage challenge, in parallel with eight of
the previous control volunteers (Group 8) and six new malaria-naive controls
(Group 9, who were recruited only from Oxford and enrolled on 5 March 2018).
This arm of the CHMI study was termed ‘‘VAC063B.’’ This second CHMI was to
investigate the durability of any vaccine effect in parallel with any protective effect
of a prior homologous challenge. All volunteers were challenged and followed up
at the CCVTM, Oxford.
Allocation to study groups was sequential from Group 1 to Group 3. Groups 3 and 4
were then recruited simultaneously. Volunteers, where possible, were able to
choose to which group they were allocated. For safety reasons the first volunteer
who received a new vaccine dose was vaccinated alone and there was at least a
48 h gap before subsequent volunteers were vaccinated. A further two volunteers
could be vaccinated 48 h after the first, and then at least another 48 h gap had to
elapse before the remaining volunteers receiving that dose of vaccine could be
vaccinated. Safety stopping and holding rules were used in this study to ensure
participant safety, particularly given that this was a first-in-human dose escalation
study, as detailed below.
Stopping / Holding Rules. Safety reviews took place prior to each dose escalation.
The following holding rules were applied to study Groups 1-5 and Group 7 (i.e., vac-
cinees). The study would have been put on hold if any of the following criteria were
reached:
Solicited local adverse events:
If more than 25% of doses of a vaccine are followed by the same Grade 3 solicited
local adverse event beginning within 2 days after vaccination (day of vaccination
and one subsequent day) and persisting at Grade 3 for > 72 h.
Solicited systemic adverse events:e5 Med 2, 701–719.e1–e19, June 11, 2021
ll
OPEN ACCESSClinical AdvancesIf more than 25% of doses of a vaccine are followed by the same Grade 3
solicited systemic adverse event beginning within 2 days after vaccination
(day of vaccination and one subsequent day) and persisting at Grade 3 for
> 48 h.
Unsolicited adverse events:
If more than 25% of volunteers develop the same Grade 3 unsolicited adverse
event (including the same laboratory adverse event) that is considered possibly,
probably or definitely related to vaccination and persists at Grade 3 for > 48 h.
A serious adverse event considered possibly, probably or definitely related to vacci-
nation occurs.
Individual stopping rules (applied to all vaccinated individuals):
In addition to the above stated group holding rules, stopping rules for individual vol-
unteers were applied (i.e., indications to withdraw individuals from further vaccina-
tions). Volunteers would have been withdrawn from further vaccinations if any of
the events listed below had occurred and were considered possibly, probably or
definitely related to vaccination:
Local Reactions: Injection site ulceration, abscess or necrosis.
Laboratory AEs: The volunteer develops a Grade 3 laboratory adverse event
considered possibly, probably or definitely related within 7 days after vaccination
and persisting continuously at Grade 3 for > 72 h.
Solicited systemic adverse events: The volunteer develops a Grade 3 systemic
solicited adverse event considered possibly, probably or definitely related within
2 days after vaccination (day of vaccination and one subsequent day) and persist-
ing continuously at Grade 3 for > 72 h.
Unsolicited adverse events: The volunteer has a Grade 3 adverse event, consid-
ered possibly, probably or definitely related to vaccination, persisting continu-
ously at Grade 3 for > 72 h.
The volunteer has a serious adverse event considered possibly, probably or defi-
nitely related to vaccination.
The volunteer has an acute allergic reaction or anaphylactic shock following the
administration of the vaccine investigational product.
Safety reviews were carried out by the Local Safety Monitor (LSM) prior to each dose
escalation (after the first six vaccinations in each of the dose groups), and no con-
cerns were raised with any of the vaccine doses.
Monitoring. The LSM provided safety oversight, and Good Clinical Practice (GCP)
compliance was independently monitored by the University of Oxford Clinical Trials
and Research Governance (CTRG) Office.
Inclusion and Exclusion Criteria. A medical history and physical examination were
conducted at the screening visit, as well as baseline blood tests including a full
blood count; urea and electrolytes; liver function tests; and hepatitis B virus
(HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) serology.
Dipstick urinalysis for all volunteers and pregnancy testing for all female volunteers
were conducted at screening, as well as an electrocardiogram for all volunteers due
to undergo CHMI (Groups 5-9). Pregnancy testing was also carried out in femaleMed 2, 701–719.e1–e19, June 11, 2021 e6
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larial therapy. A full list of inclusion and exclusion criteria is shown below:
—Inclusion criteria. Volunteers had to satisfy all the following criteria to be eligible
for the study:
Healthy adults aged 18 to 45 years.
Able and willing (in the Investigator’s opinion) to comply with all study require-
ments.
Willing to allow the Investigators to discuss the volunteer’s medical history with
their General Practitioner (GP).
For females only, willingness to practice continuous effective contraception (see
below) during the study and a negative pregnancy test on the day(s) of screening
and vaccination, and on the day prior to blood-stage CHMI, and prior to the start
of antimalarial treatment for Groups 5-9 volunteers.
Agreement to refrain from blood donation during the course of the study.
Provide written informed consent.
—Additional Inclusion Criteria for Groups 5 - 9. Agreement to permanently refrain
from blood donation, as per current UK Blood Transfusion and Tissue Transplanta-
tion Services guidelines.62
Reachable (24 hours a day) by mobile phone during the period between CHMI
and completion of antimalarial treatment.
Willingness to take a curative anti-malaria regimen following CHMI.
Answer all questions on the informed consent questionnaire correctly.
For Groups 7-9: completion of primary challenge, curative anti-malarials and
follow-up (up until at least the dC+28 visit)
—Exclusion Criteria. Volunteers were not eligible to participate if any of the
following applied:
Participation in another research study involving receipt of an investigational
product in the 30 days preceding enrolment, or planned use during the study
period.
Prior receipt of an investigational vaccine likely to impact on interpretation of the
trial data, as assessed by the investigator. For Group 7 volunteers undergoing re-
challenge, this exclusion criterion does not extend to the RH5.1/AS01B vaccine
previously received.
Any medical condition that in the judgment of the Investigator would make intra-
muscular (IM) injection unsafe.
Administration of immunoglobulins and/or any blood products within the three
months preceding the planned administration of the vaccine candidate.
Any confirmed or suspected immunosuppressive or immunodeficient state,
including HIV infection; asplenia; recurrent, severe infections and chronic (more
than 14 days) immunosuppressant medication during the period starting six
months prior to the first vaccine dose. For corticosteroids, this will mean predni-
sone 20 mg/day (for adult subjects), or equivalent. Inhaled and topical steroids
are allowed.
Administration of long-acting immune-modifying drugs at any time during the
study period (e.g., infliximab).e7 Med 2, 701–719.e1–e19, June 11, 2021
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tologic patients, sulfa for recurrent urinary tract infections, etc.).
History of malaria chemoprophylaxis within 60 days prior to vaccination.
History of allergic disease or reactions likely to be exacerbated by any compo-
nent of the vaccine.
Any history of anaphylaxis in relation to vaccination.
Pregnancy, lactation or willingness/intention to become pregnant during the
study.
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma
in situ).
History of serious psychiatric condition likely to affect participation in the study.
Any other serious chronic illness requiring hospital specialist supervision.
Suspected or known current alcohol abuse as defined by an alcohol intake of
greater than 42 units every week.
Suspected or known injecting drug abuse in the 5 years preceding enrolment.
Seropositive for hepatitis B surface antigen (HBsAg).
Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless has
taken part in a prior hepatitis C vaccine study with confirmed negative HCV anti-
bodies prior to participation in that study, and negative HCV RNA PCR at
screening for this study).
History of clinical malaria (any species; not applicable to prior CHMI for Groups 7,
8 and 9).
Travel to a malaria endemic region during the study period or within the previous
six months.
Any clinically significant abnormal finding on screening biochemistry or hematol-
ogy blood tests or urinalysis.
Any other significant disease, disorder or finding which may significantly increase
the risk to the volunteer because of participation in the study, affect the ability of
the volunteer to participate in the study or impair interpretation of the study data.
Inability of the study team to contact the volunteer’s GP to confirm medical his-
tory and safety to participate.
—Additional Exclusion Criteria for Groups 5-9. Use of systemic antibiotics with
known antimalarial activity within 30 days of CHMI (e.g., trimethoprim-sulfamethox-
azole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and
azithromycin).
History of sickle cell anemia, sickle cell trait, thalassaemia or thalassaemia trait or
any hematological condition that could affect susceptibility to malaria infection.
Laboratory evidence of glucose-6-phosphate dehydrogenase (G6PD) deficiency
at screening.
Laboratory evidence of haemoglobinopathy at screening.
Use of medications known to cause prolongation of the QT interval and existing
contraindication to the use of Malarone.
Use of medications known to have a potentially clinically significant interaction
with Riamet and Malarone.
Contraindications to the use of both Riamet and Malarone.
Any clinical condition known to prolong the QT interval.
Family history of congenital QT prolongation or sudden death.
Positive family history in both 1st and 2nd degree relatives < 50 years old for car-
diac disease.
History of cardiac arrhythmia, including clinically relevant bradycardia.Med 2, 701–719.e1–e19, June 11, 2021 e8
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reasons.
Safety Analysis. Following each vaccination, volunteers completed an electronic di-
ary card for 28 days with any AE data. Participants were asked to record both soli-
cited and unsolicited AEs. Data on solicited AEs were collected for 7 days after
each vaccination, whereas details of any unsolicited AEs were collected for the dura-
tion of each diary. Solicited AEs were those expected following an intramuscular
vaccination and included local AEs (pain, erythema, warmth, swelling and itching)
and systemic AEs (headache, malaise, myalgia, arthralgia, feverishness, nausea, fa-
tigue, and measured fever). If these AEs occurred outside of the first seven days they
were defined as unsolicited. Any solicited AEs occurring during the diary card period
were defined as being at least possibly related to vaccination.
Volunteers graded all AEs as mild, moderate or severe:
GRADE 0: None.
GRADE 1: Transient or mild discomfort (< 48 h); no medical intervention/therapy
required.
GRADE 2: Mild to moderate limitation in activity – some assistance may be
needed; no or minimal medical intervention/therapy required.
GRADE 3: Marked limitation in activity, some assistance usually required; medical
intervention/therapy required; hospitalization possible.
AE data also included the results of the hematology (full blood count) and biochem-
istry (liver function tests, urea and electrolytes) carried out at all visits during the diary
card period, except at 2 days post-vaccination, when blood was not taken.
For each unsolicited AE, an assessment of the relationship of the AE to the study in-
tervention(s) was undertaken. Alternative causes of the AE, such as the natural his-
tory of pre-existing medical conditions, concomitant therapy, other risk factors
and the temporal relationship of the event to vaccination were considered. The likely
causality of all unsolicited AEs was assessed as per the criteria below:
No Relationship: No temporal relationship to study product and alternate etiol-
ogy (clinical state, environmental or other interventions); and does not follow
known pattern of response to study product.
Unlikely: Unlikely temporal relationship to study product and alternate etiology
likely (clinical state, environmental or other interventions) and does not follow
known typical or plausible pattern of response to study product.
Possible: Reasonable temporal relationship to study product; or event not readily
produced by clinical state, environmental or other interventions; or similar
pattern of response to that seen with other vaccines.
Probable: Reasonable temporal relationship to study product; and event not
readily produced by clinical state, environment, or other interventions or known
pattern of response seen with other vaccines.
Definite: Reasonable temporal relationship to study product; and event not
readily produced by clinical state, environment, or other interventions; and
known pattern of response seen with other vaccines.
All unsolicited AEs that were assessed as being possibly, probably or definitely
related to RH5.1/AS01B are shown in Data S1B.e9 Med 2, 701–719.e1–e19, June 11, 2021
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cinees) and data on serious adverse events (SAEs) were collected for all groups
throughout the study period.
—AEs in the post-CHMI period. Post-CHMI, volunteers were asked if they had expe-
rienced solicited malaria symptoms, and asked to grade these (as above). Data on
AEs occurring during and after the CHMI period (that may have related to CHMI
or antimalarial treatment) were collected at clinic visits, from dC+1 up until
90 days post-CHMI. These CHMI-related safety data will be fully reported elsewhere
(Y.T., unpublished data).
Follow-upSchedule.Vaccination visits occurredondays 0, 28and56 (Groups1, 2, 4 and
5) anddays 0, 28, 182 (Group3). Group 7 received a fourth and final vaccination 98days
(fourteen weeks) post-CHMI (and 112 days, sixteen weeks post-third vaccination).
Reviews post-vaccination for Groups 1, 2 and 4 occurred on Days 1, 7, 14, 29, 35, 42,
57, 63, 70, 84, 140 and 240. Reviews for Group 3 were on Days 1, 7, 14, 29, 35, 42, 56,
183, 189, 196, 210, 266 and 366. Reviews for Group 5 were as per Groups 1, 2 and 4,
until day 63. They then attended on day 69 – the day before challenge (dC-1 visit) –
and underwent CHMI fourteen days post-final vaccination. Reviews post-vaccination
for Group 7 – i.e., after the final and fourth vaccination – were as for Group 5,
including a day 1 and day 7 visit post-vaccination, with a dC-1 visit and CHMI
14 days after the final vaccination. Volunteers in Groups 5-9 were reviewed in clinic
the day after challenge (dC+1), twice a day from dC+2 until dC+12, then once daily
from dC+13 (if not yet diagnosed) until dC+21 (or diagnosis). Upon malaria diag-
nosis or dC+21 being reached, subjects were reviewed approximately 24 and 48 h
after diagnosis and / or starting antimalarial therapy, then at dC+28 and finally at
dC+90. Group 5 additionally attended for a dC+170 visit.
Volunteers were invited back for a final ‘‘late bleed’’ approximately 1.5-2.5 years af-
ter the first vaccination in order to assess the longevity of the vaccine-induced
response. Thirty of the vaccinated volunteers in Groups 1-4 (at day 875, 663 and
626 (median) for Groups 1, 2 and 4 respectively, and at day 687 (median) in Group
3) returned for a late bleed visit. Additionally, three of the volunteers in Group 5
(at day 643, median) and six in Group 7 (at day 643, median) underwent a late bleed.
Vaccine Safety – Extra Information. Solicited adverse events (AEs) in Groups 1-4, 5
and 7 were primarily mild to moderate in severity; however, occasional severe AEs
occurred (Figures S2 and S7). The majority of these solicited AEs lasted for approx-
imately 24-48 hours following vaccination. The unsolicited AEs considered possibly,
probably or definitely related to the vaccine are shown in Data S1B. The majority
were mild in nature and all resolved spontaneously. One Group 5 volunteer devel-
oped mild bilateral infraorbital swelling within 24 h of their second vaccination.
They had no other features of an allergic reaction, required no clinical intervention,
and the swelling had completely resolved within 48 hours. The volunteer was, how-
ever, withdrawn from the study due to the possibility that this represented a mild
allergic reaction.
A single occurrence of scalp psoriasis in one Group 3 volunteer was retrospectively
regraded a suspected unexpected serious adverse reaction (SUSAR) on the basis of i)
its likely autoimmune nature (all new/suspected autoimmune events were collected
as AEs of special interest and therefore reported as SAEs, as for previous clinical tri-
als of vaccines using the AS01B adjuvant); and ii) its potentially plausible time ofMed 2, 701–719.e1–e19, June 11, 2021 e10
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a causal relationship ‘‘possible,’’ despite being unlikely clinically.
Four grade 3 laboratory AEs were reported in vaccinated participants (prior to CHMI)
(Data S1A): A grade 3 lymphocytopenia occurred in one volunteer in Group 1 occur-
ring on day 6 post-first vaccination. This was not felt to be related to vaccination as
the volunteer became unwell with malaise, nausea, muscle aches, feverishness and
diarrhea starting de novo 6 days post-vaccination, having been completely well
prior. The symptoms and lymphocytopenia resolved spontaneously within 72 hours.
A grade 3 hyperkalaemia occurred in one Group 1 volunteer 7 days post-third vacci-
nation, but was reported by the testing laboratory as a haemolysed sample and had
normalized on repeat testing 72 hours later. A grade 3 hypoalbuminemia (9 g/dL)
was reported in one Group 5 volunteer at day14 post-first vaccination. However,
this was reported by the lab as a spurious result, and was within the normal range
when re-checked 2 days later. Finally, a grade 3 anemia (Hb 88 g/dL) occurred in
oneGroup 4 volunteer at days 7 and 14 post-first vaccination. However, this was sub-
sequently found to be a preceding condition for which the volunteer was under
investigation and treatment (not initially apparent at screening), and so the volunteer
was withdrawn from the study.
One volunteer in Group 7 fell pregnant following her fourth 10 mg dose of the vaccine
and her second blood-stage CHMI (pregnancy testing by urinary b-HCG prior to
challenge was negative). Pregnancy was first detected by urinary b-HCG testing
on day 9 post-challenge, following routine testing at time-point of malaria diagnosis,
just prior to treatment. Following immediate discussion between the Chief Investi-
gator and the Local Safety Monitor, this volunteer was treated with Riamet. Preg-
nancy was also confirmed within 24 hours by serum b-HCG testing. The volunteer
was closely monitored over the treatment phase and afterward with no further clin-
ical concerns arising. There was no detectable malaria DNA by qPCR after 3 weeks.
She remained well and went on to have a termination of pregnancy about 2 months
later for personal reasons.
Blood-Stage Inoculum and CHMI. The inoculum used for CHMI was produced at
QIMR Berghofer Medical Research Institute in Brisbane, Australia in 1994 and con-
sists of aliquots of P. falciparum (clone 3D7) infected erythrocytes taken from a single
donor.60,63,64 Over 400 volunteers have been challenged with the inoculum since
1997 (79 in Oxford inclusive of the VAC063 trial), and the estimated number of in-
fected erythrocytes has varied from 30 to 6000. CHMI of malaria-naive individuals
using this inoculum has always resulted in parasitemia as detected by qPCR and/
or microscopy.63,64 All volunteers within VAC063A and within VAC063B were chal-
lenged with the same preparation of the inoculum. The intended inoculum was
1000 infected erythrocytes per volunteer, thawed and prepared under strict aseptic
conditions as previously described,18 with some modifications. Briefly, a single vial
of cryopreserved erythrocytes was thawed in a derogated containment level III lab-
oratory area using solutions licensed for clinical use and single-use disposable con-
sumables. A class II microbiological safety cabinet (MSC) was used to prepare the
inoculum, which was fumigated with hydrogen peroxide and decontamination vali-
dated prior to use. To prepare the inoculum, 0.2 volume 12% saline was added drop-
wise to 1.5 mL of thawed infected blood, left for 5 min, and an additional 10 vol-
umes of 1.6% saline added dropwise. This was centrifuged for 4 min at 830 xg,
the supernatant was removed, and 10 mL of 0.9% saline was added dropwise. The
cell pellet was washed twice in 0.9% saline and resuspended in 0.9% saline in a sterile
syringe for injection. The injection volume per volunteer was 5 mL containing ane11 Med 2, 701–719.e1–e19, June 11, 2021
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nor’s parasite density prior to freezing. The clinical inoculum was also cultured
following preparation and shown to be negative for bacterial contamination. The or-
der in which vaccinated and unvaccinated volunteers received the inoculum was
interspersed in case of time effects on viability of the parasites. All subjects were
inoculated intravenously, in a total volume of 5 mL of normal saline followed by a sa-
line flush, within 2 h 6 min of inoculum preparation (VAC063A) and 2 h 8 min of inoc-
ulum preparation (VAC063B). Subjects were observed for 1 h before discharge from
the clinical facility.
Diagnostic Criteria. For VAC063A (Groups 5 and 6), at each time-point thick blood films
were evaluated by experienced microscopists and qPCR was performed in real time.
Diagnosis of malaria required volunteers to fulfil two of three criteria: a positive thick
blood film (one viable parasite in 200 fields) and/or qPCR R 500 parasites/mL (p/mL)
and/or symptoms consistent with malaria infection. However, in VAC063B (Groups 7-
9) microscopywas removed as a diagnostic tool. This reduced the number of volunteers
diagnosed prematurely (i.e., < 5,000 p/mL) in VAC063B (Figure S8E) without impacting
on volunteer safety. In light of the above, the new criteria for diagnosis and immediate
treatment of volunteers in VAC063B (Groups 7-9), were:
Asymptomatic with any available qPCR result R 10,000 parasites/mL;
Symptomatic with any available qPCR result R 5,000 parasites/mL.
At diagnosis volunteers were treated with Riamet (except for 4 volunteers who
received Malarone due to documented sinus bradycardia pre-challenge, and one
who received Malarone due to a potential concomitant medication interaction
with Riamet). Follow-up visits took place at days dC+28 and dC+90.
METHOD DETAILS
Inoculum Viability
Parasite viability was assayed by limiting dilution assay, as described previously,18
and was setup at the time the last volunteer was infected. In brief, the culture period
was 10 days and after this time qPCR was used to score wells positive or negative for
replicating parasites. Because the qPCR assay can also detect dead parasites, a plate
of identical dilutions of the inoculum that had been frozen without incubation was
used as a negative control; there was no detectable amplification from these wells,
and unincubated control wells which had received a 100-fold greater parasite inoc-
ulum gave positive results. Cultured wells plated at an estimated 1.5 parasites/well
gave a clear bimodal distribution, with wells showing negative results by qPCR (sug-
gesting they contained no viable parasite), and wells that gave highly positive results
by qPCR (suggesting they had contained at least one viable parasite at the start of
the culture period). The number of viable parasites/mL of inoculum could then be
calculated with reference to the Poisson distribution, and viability expressed as a
percentage of the pre-freezing microscopy-estimated parasitemia calculated using
the RBC count/mL of inoculum. For VAC063A, the limiting dilution assay demon-
strated 45.2% viability (i.e., an effective inoculum of 452 parasites per volunteer),
and for VAC063B this was 85.7% viability (i.e., 857 parasites per volunteer).
Parasite qPCR
qPCR was conducted as previously described,18 with the following modifications.
Briefly, blood was collected at baseline and at clinical protocol defined time-points
following CHMI for qPCR in 2.0 mL tubes containing EDTA. DNA was extracted from
0.4mL EDTAwhole blood using aQIAsymphony SP robot, utilizing theQIAGENDSPMed 2, 701–719.e1–e19, June 11, 2021 e12
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elution in ATE buffer selected. 5 mL of each extraction was used per assay well and
was run in triplicate for qPCR (equivalent to 60 mL blood directly assessed). Parasites
per mL (p/mL) equivalent mean values were generated by a standard Taqman abso-
lute quantitation, against a defined standard curve of diluted P. falciparum 3D7
DNA, qualified against DNA from counted parasites in whole blood, previously ex-
tracted by the samemethod. qPCR was conducted on an ABI StepOne Plus machine
with v2.3 software, using default Universal qPCR andQC settings, apart from the use
of 45 cycles and 25 mL reaction volume. This process has since been formally vali-
dated as suitable for diagnostic purposes and qPCR detection is regularly externally
assessed by participation in the UKNEQAS Malaria (Molecular) scheme.
Based upon results obtained using dilution series of microscopically-counted
cultured parasites, this method has a lower limit of quantification (LLQ, defined as
%CV < 20%) of around 20 p/mL blood.27 Counted parasite dilution series results
suggest that the lower limit of probable detection (LLD, i.e., a probability of >
50% of R 1 positive result among three replicate qPCR reactions) is in the region
of 5 p/mL, while samples at 1 p/mL are consistently negative (24/24 qPCR reactions).
Positive results in this assay (even at very low level) are thus essentially 100% specific
for genuine parasitemia, with positive results beneath the LLQ likely to signify para-
sitemia in the range 2-20 p/mL.
For quality control purposes, qPCR samples were re-tested if;
Replicates included a mixture of positive and negative (in terms of amplification)
results with one or more positive results > 100 p/mL.
The % CV of any results were high outliers.
All ‘passed’ data following quality control QC steps above, including any 0 values,
were used to generate the mean result for each time-point.
Peripheral Blood Mononuclear Cell (PBMC), Plasma and Serum Preparation
Blood samples were collected into lithium heparin-treated vacutainer blood collec-
tion systems (Becton Dickinson, UK). PBMC were isolated and used within 6 hours in
fresh assays as previously described.65 Excess cells were frozen in fetal calf serum
(FCS) containing 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen.
Plasma samples were stored at80C. For serum preparation, untreated blood sam-
ples were stored at room temperature (RT) and then the clotted blood was centri-
fuged for 5 min (1000 xg). Serum was stored at 80C.
Peptides
Peptides for ex-vivo IFN-g ELISPOT were purchased from NEO Scientific (Cam-
bridge, MA, USA). Sequences have been reported previously,11 although eight of
these were replaced with slight sequence changes to provide exact match to the
RH5.1 vaccine. In brief, the peptides (20 amino acids (aa) in length and overlapping
by 10 aa) covered the entire RH5 sequence present in the RH5.1 protein vaccine.
Peptides were reconstituted in 100% DMSO at 50-200 mg/mL and combined into
various pools for the ELISPOT assay.
Recombinant RH5 Protein
Recombinant RH5.1 protein was used for all ELISA assays, B and T cell ELISPOT as-
says and flow cytometry assays. The protein was produced and purified from a stably
transfected Drosophila S2 cell line as previously described.11,21e13 Med 2, 701–719.e1–e19, June 11, 2021
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Fresh PBMC were used in all assays using a previously described protocol.11 Spots
were counted using an ELISPOT counter (Autoimmun Diagnostika (AID), Germany).
Results are expressed as IFN-g spot-forming units (SFU) per million PBMC. Back-
ground responses in unstimulated control wells were almost always less than 20
spots, and were subtracted from those measured in peptide-stimulated wells.
Flow Cytometry
RH5.1-specific CD4+, CD8+ and CD4+ Tfh cells were analyzed with an activation
induced marker (AIM) assay as previously described,66 with the exception of stimu-
lation with RH5.1 protein rather than a peptide pool, and the addition of brefeldin A
(BFA; 00-4506-51, Life Technologies). Briefly, cryopreserved PBMC were thawed
and rested before stimulation for 24 h with medium alone, 1 mg/mL RH5.1, or
1 mg/mL Staphylococcal enterotoxin B (SEB; S-4881, Sigma; positive control). BFA
was included for the final 2 h of stimulation at 3 mg/mL. Medium only served as a
negative control. Anti-human CD183-APC (550967, clone: 1C6/CXCR3; BD Biosci-
ences) was included in the cell culture medium. Following incubation, PBMC were
stained and fixed with Cytofix/Cytoperm (554714, BD Biosciences). The following
anti-human antibodies / dyes were used: anti-PD1-BV421 (329920, clone:
EH12.2H7), anti-CD14-BV510 (301842, clone: M5E2), anti-CCR6-BV711 (353436,
clone: G034E3), anti-CD3-BV605 (300460, clone: UCHT1), anti-CD137-BV650
(309828, clone: 4B4-1), and anti-CD45RO-BV785 (304234, clone: UCHL1) – all Bio-
legend; anti-CD19-BV510 (562947, clone: SJ25C1), anti-CD69-PE-Cy5 (555532,
clone: FN50), anti-CXCR5-AF700 (565191, clone: RF8B2), anti-CD4-APC-H7
(641398, clone: SK3), anti-OX40-PE (340420, clone: L106), anti-CD25-PE-Cy7
(335824, clone: 2A3), and streptavidin-BB515 (564453) – all BD Biosciences); anti-
IFN-g-PerCP-Cy5.5 (45-7319-42, clone: 42.B3), and anti-CD8-PE-TR (MHCD 0817,
clone: 3B5) – both Life Technologies; Live/Dead Aqua (L34966), and anti-ICOS-
biotin (13-9948-82, clone: ISA-3) – both Invitrogen. Samples were acquired on a For-
tessa flow cytometer using BD FACSDiva (both BD Biosciences) and data were
analyzed in FlowJo (v10, Treestar). For the Tfh cell analysis, RH5.1-specific cells
were defined using Boolean gating as cells co-expressing CD25 with OX40 and/or
CD137 and/or CD69 following stimulation with RH5.1. Frequencies of total CD4+
and CD8+ T cells producing IFN-g in response to RH5.1 stimulation were measured
in the same assay. For both Tfh cells and IFN-g-producing T cells, the frequency of
activated cells in sample-matched unstimulated wells was subtracted to control for
non-specific activation. Samples were excluded from analysis if the parent popula-
tion contained < 50 cells.
Total IgG ELISAs
ELISAs were performed against full-length RH5 protein (RH5.1) using standardized
methodology as previously described.11 The reciprocal of the test sample dilution
giving an optical density at 405nm (OD405) of 1.0 in the standardized assay was
used to assign an ELISA unit value of the standard. A standard curve and Gen5 ELISA
software v3.04 (BioTek, UK) was used to convert the OD405 of individual test samples
into arbitrary units (AU). These responses in AU are reported in mg/mL following gen-
eration of a conversion factor by calibration-free concentration analysis (CFCA) as re-
ported previously.11
Avidity and Isotype/Subclass ELISAs
Anti-RH5.1 IgG antibody avidity was assessed by sodium thiocyanate (NaSCN)-
displacement ELISA using previously described methodology.11 The concentration
of NaSCN required to reduce the OD405 to 50% of that without NaSCNwas used as aMed 2, 701–719.e1–e19, June 11, 2021 e14
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performed using methodology described in detail elsewhere.11
Antibody-Secreting Cell (ASC) ELISPOT
Ex-vivo ASC ELISPOT assays were performed against RH5.1 protein as described in
detail elsewhere11 using fresh PBMC. Plates were counted using an AID ELISPOT
plate reader. Results are reported as RH5_FL-specific ASC as a % of the total number
of measured IgG-secreting B cells.
Serum IgG Concentration
Total serum IgG concentrations were determined using a Bio-Monolith Protein G col-
umn on an Agilent 1260 HPLC system (Agilent, Cheshire, UK). Separation was per-
formed at 1 mL/min using PBS and 0.2MGlycine pH 2.0 as mobile phases with detec-
tion at UV 280 nm. A calibration curve was produced using purified human IgG.
Assay of Growth Inhibition Activity (GIA)
Standardized assays were performed by the GIA Reference Center, NIH, USA, using
previously described methodology,67 with one modification. Here, each sample was
tested in three independent replication assays, and themedian of these three results
was used to generate the final dataset. Otherwise for each assay, in brief, protein G
purified IgG samples were incubated with red blood cells (RBC) infected with syn-
chronized P. falciparum 3D7 clone parasites in a final volume of 40 mL for 40 h at
37C, and the final parasitemia in each well was quantified by biochemical determi-
nation of parasite lactate dehydrogenase. All samples were tested at 10mg/mL in a
final test well, followed by a dilution series for positive samples to determine the con-
centration that gave 50% GIA (EC50).
Viral-Vectored RH5 Trial Data
Where specifically referred to in the text, historical data were included for compar-
ison from the VAC057 Phase Ia clinical trial of a viral-vectored RH5 (VV-RH5) vac-
cine.11 RH5-specific immune readouts were measured in an identical manner across
the different clinical trials. Serology/GIA (day 84) and T cell ELISPOT (day 63) assay
data for the VV-RH5 vaccine are shown from Group 2C in that trial.
FMP2.1 AMA1/AS01 Trial Data
Where specifically referred to in the text, historical data were included for compar-
ison from the VAC054 Phase I/IIa clinical trial of the FMP2.1 AMA1/AS01 vaccine.18
PMR efficacy and GIA assay readouts were measured in an identical manner across
the different clinical trials.
Systems Serology Analyses
Experimenters at Massachusetts General Hospital (MGH) were blinded as to the
sample identity until all data had been collected. Assays performed at MGH using
plasma samples from the VAC063 trial were deemed not human research following
review by the MGH Institutional Review Board (protocol 2012P002452). Addition-
ally, human whole blood and buffy coats were collected at MGH from healthy donors
who did not participate in the VAC063 trial. Use of these internal samples as sources
of uninfected primary neutrophils and NK cells was deemed not human research by
the MGH IRB (protocols 2010P002121 and 2005P001218).
Fluorescent Primary and Secondary Antibodies
The following fluorescent antibodies were purchased fromBDBiosciences: APC-Cy7
anti-huCD14 (#557831), PE-Cy7 anti-huCD3 (#563423), PE-Cy7 anti-huCD56e15 Med 2, 701–719.e1–e19, June 11, 2021
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were purchased from BioLegend: Pacific Blue anti-huCD66b (#305112), APC-Cy7
anti-huCD3 (#300426), BV605 anti-huCD107a (#328634), and PE anti-huIFN-g
(#506507). A FITC-conjugated, goat anti-guinea pig complement C3 polyclonal
antibody was purchased fromMP Biomedical (#0855385). PE-conjugated secondary
antibodies were purchased from Southern Biotech for the detection of total huIgG
(#9040-09), huIgM (#9020-09), huIgA1 (#9130-09), huIgA2 (#9140-09), huIgG1
(#9052-09), huIgG2 (#9070-09), huIgG3 (#9210-09), and huIgG4 (#9200-09).
Antigen Coupling to Fluorescent Beads
NeutrAvidin-labeled yellow-green (#F8776) and red (#F8775) fluorescent 1 mm mi-
crospheres were purchased from Thermo Fisher Scientific. For immune functional as-
says, 1.8 3 108 NeutrAvidin-labeled fluorescent microspheres were coupled to 5 mg
biotinylated PfRH5 antigen (exact construct described in Nielsen et al.66) by co-incu-
bation in PBS/5% BSA (PBSA) overnight at 4C, then the beads were washed twice
with PBSA. Magplex-C microspheres (Luminex Corp) were covalently coupled to
streptavidin (Jackson Immunoresearch, #016-000-113) using a two-step carbodii-
mide reaction. Magplex-C beads (9 3 108) were washed, resuspended in 100 mM
NaH2PO4 (pH 6.2), and activated by incubating with 500 mg Sulfo-NHS (Pierce,
#A39269) and 500 mg EDC (Pierce, #A35391) for 30 min at room temperature (RT).
The beads were washed three times with coupling buffer (50 mM MES, pH 5.0),
then incubated with streptavidin in 500 mL of coupling buffer for 2 h at RT. The beads
were washed with PBS/0.05% Tween-20, incubated overnight at 4Cwith 100 mg/mL
biotinylated PfRH5 in PBSA, washed, and stored in PBS/0.05% sodium azide.
THP-1 Monocyte Phagocytosis Assay
An assay for measuring antibody-dependent THP-1 monocyte / cellular phagocy-
tosis (ADCP) was used as previously described.68 Briefly, 1 mm yellow-green fluores-
cent NeutrAvidin beads were coupled to biotinylated PfRH5 antigen and blocked
overnight with PBSA. The beads were then washed twice with PBSA, diluted to
1.8 3 108 beads/mL, and 10 mL beads/well were added to a 96-well round-bottom
microplate. Diluted plasma from immunized subjects (10 mL/well) was added to the
beads and incubated at 37C for 2 h to allow the formation of immune complexes.
Unbound antibodies were washed off, then 25,000 THP-1 cells/well (ATCC, #TIB-
202) were added to the beads in 200 mL THP-1 medium (R-10 + 55 mM b-ME) and
incubated overnight at 37C. Cells were fixed and acquired on an Intellicyt iQue
Screener PLUS flow cytometer. The phagocytic score for each sample was calculated
as (% bead-positive cells) x (gMFI of bead-positive cells)/(10 x gMFI of first bead-pos-
itive peak).
Primary Neutrophil Phagocytosis Assay
An assay for measuring antibody-dependent neutrophil phagocytosis (ADNP) has
been described previously.69 Briefly, 1 mm yellow-green fluorescent NeutrAvidin
beads were coupled to biotinylated PfRH5 antigen and blocked with PBSA overnight
at 4C. The beads were then washed twice with PBSA and diluted to 1.8 3 108
beads/mL. PfRH5-coupled beads (10 mL/well) and diluted test plasma (10 mL/well)
were combined in a round-bottom 96-well plate, then incubated at 37C for 2 h. Pri-
mary leukocytes were isolated from freshly drawn whole blood (collected from
healthy donors in anticoagulant citrate dextrose tubes) by treatment with ACK red
blood cell lysis buffer, then diluted in R-10 media to 250,000 cells/mL. After immune
complex formation, the beads were washed, combined with 50,000 primary leuko-
cytes/well, and incubated for 1 h at 37C. Cells were stained for surface CD66b,
CD14, and CD3, fixed, and acquired on an Intellicyt iQue Screener PLUS flowMed 2, 701–719.e1–e19, June 11, 2021 e16
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and phagocytic scores for each sample were calculated as (% bead-positive cells) x
(gMFI of bead-positive cells)/(10 x gMFI of the first bead-positive peak).
Complement Deposition Assay
An assay for measuring antibody-dependent complement deposition (ADCD) was
used as previously described.70 Briefly, 1 mm red fluorescent NeutrAvidin beads
were incubated with biotinylated PfRH5 antigen, blocked with PBSA, then washed
and diluted to 1.8 3 108 beads/mL. PfRH5-coupled beads (10 mL/well) were com-
bined with diluted test plasma (10 mL/well) in a 96-well round-bottom microplate,
then incubated at 37C for 2 h. Guinea pig complement (CedarLane, #CL4051)
was diluted in gelatin veronal buffer containing calcium and magnesium (GVB++,
Boston Bioproducts, #IBB-300). The beads were washed with PBS and incubated
with diluted complement for 20 min at 37C. The beads were then washed with
5 mM EDTA, stained with FITC-conjugated anti-complement C3, and acquired on
an Intellicyt iQue Screener PLUS flow cytometer. Gates were drawn on singlet, red
fluorescent particles, and complement deposition was reported as the median fluo-
rescence intensity (MFI) on the FITC channel.
NK cell Activation Assay
An assay for measuring antibody-dependent NK cell activation (ADNKA) has been
described previously.71,72 Flat-bottom 96-well ELISA plates (Thermo Fisher,
#439454) were coated with biotinylated PfRH5 antigen, then blocked with PBSA.
Plasma samples from test subjects were diluted in PBSA, added to the plates, and
incubated for 2 h at 37C. Primary human NK cells were purified from buffy coats
from healthy donors using the RosetteSep human NK cell enrichment cocktail (Stem-
Cell, #15065), then resuspended in R-10 media containing 10 mg/mL brefeldin A
(Sigma, #B7651), GolgiStop (BD Biosciences, #554724), and fluorescent anti-
CD107a. The ELISA plates were washed three times with PBS, then isolated NK cells
(25,000/well) were added and incubated at 37C for 5 h. The cells were then stained
for surface CD56 and CD3, permeabilized, stained with fluorescent antibodies to
IFN-g and MIP-1b, fixed, and acquired on an Intellicyt iQue Screener PLUS flow cy-
tometer. Gates were drawn on singlet, CD56+/CD3- cells, and results were reported
as the percentages of these cells that expressed surface CD107a, intracellular MIP-
1b, or intracellular IFN-g.
Antibody Isotype and Subclass Analysis
The isotypes and subclasses of PfRH5 antigen-specific antibodies were quantified
using a previously described method.73 Magplex-C microspheres were coupled to
streptavidin via carbodiimide crosslinking with Sulfo-NHS and EDC. Streptavidin-
coupled beads were then incubated overnight with biotinylated PfRH5 antigen,
blocked with PBSA, and added to black flat-bottom 384-well plates (Greiner Bio-
One, #781906) so that each well contained 1500 RH5-coupled beads. Plasma from
test subjects was diluted in PBSA and co-incubated with the beads for 2 h at RT
on a plate shaker (800 rpm). The beads were then washed and incubated with a
PE-conjugated antibody to detect total human IgG, huIgG1, huIgG2, huIgG3,
huIgG4, huIgM, huIgA1, or huIgA2 for 1 h at RT on a plate shaker (800 rpm). The
beads were then washed and acquired on an Intellicyt iQue Screener PLUS flow cy-
tometer. Results were reported as the median PE fluorescence intensity.
Fc-binding Protein Array
The binding of PfRH5 antigen-specific antibodies to human Fc receptors (FcR) and
complement C1q was measured using a previously-described assay.74,75 Briefly,e17 Med 2, 701–719.e1–e19, June 11, 2021
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purified by the Duke Human Vaccine Institute Protein Production Facility. These pro-
teins were then biotinylated with BirA ligase using a commercially available kit (Avid-
ity, #BirA500). Purified human C1q protein (Sigma, #C1740) was biotinylated using
EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce, #A35358) according to the manufacturer’s
instructions. These biotinylated Fc domain-binding proteins were then incubated
with streptavidin-PE (Prozyme, #PJ31S) to generate the assay detection reagents.
Magplex-C microspheres were coupled to biotinylated PfRH5 antigen as described
above, blocked with PBSA, and added to 384-well plates so that each well contained
1500 RH5-coupled beads. Plasma from test subjects was diluted in PBSA, added to
the beads, and incubated for 2 h at RT on a plate shaker (800 rpm). The beads were
then washed, incubated with one of the PE/FcR conjugates for 1 h at RT on a plate
shaker (800 rpm), washed again, and acquired on an Intellicyt iQue Screener PLUS
flow cytometer. Results were reported as the median PE fluorescence intensity.
Fc glycan Analysis
The Fc glycans on RH5 antigen-specific IgG were analyzed using a previously
described method.76,77 Briefly, 200 mL of plasma from each vaccinated subject
was heat-inactivated at 56C for 1 h, then centrifuged at 20,000 xg for 10 min at
RT. The resulting supernatant samples were first pre-cleared by incubating with
1 mm magnetic streptavidin-coated microspheres (New England Biolabs, #S1420S)
for 1 h at RT. A magnet was used to pellet the beads, and the supernatants were
then transferred to new tubes containing streptavidin-coated beads that had been
coupled to biotinylated PfRH5 antigen. The PfRH5-coupled beads were incubated
with plasma samples for 1 h at 37C, then washed and incubated with IdeZ enzyme
(New England Biolabs, #P0770S) for 1 h at 37C to remove the Fc fragments from the
bead-bound antibodies. These Fc fragments were transferred to new tubes and
incubated with PNGase F (Applied Biosystems, #A28404) for 1 h at 50C to remove
the glycans. The glycans were then isolated and labeled with APTS dye using a Gly-
canAssure kit (Thermo Fisher, #A28676) according to the manufacturer’s instruc-
tions. Finally, APTS-labeled glycan samples were analyzed by capillary electropho-
resis on an ABI 3500xL Genetic Analyzer. The area under the peak for each Fc
glycan structure was calculated using GlycanAssure data analysis software. Results
were then reported as the frequency (%) of each glycan structure within a given
sample.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise stated, data were analyzed using GraphPad Prism version 8.3.1 for
Windows (GraphPad Software Inc.). All tests used were 2-tailed and are described in
the text, along with the protocol pre-specified analyses in the relevant Results sec-
tions. To analyze the relationship between GIA and ELISA assay data, a Richard’s
five-parameter dose-response curve was fitted, constrained to 0%GIA at the bottom
and 100% GIA at the top. A value of p < 0.05 was considered significant.
Modeling of PMR
qPCR-derived PMR was pre-specified in the VAC063 trial protocol as the primary ef-
ficacy endpoint, and the comparison of the endpoint between the two groups in
VAC063A constituted the pre-specified primary analysis for RH5.1/AS01B vaccine ef-
ficacy. PMR was modeled as previously reported;44 here, in order to model the PMR,
the arithmetic mean of the three replicate qPCR results obtained for each individual
at each time-point was used for model-fitting. Negative individual replicates were
assigned a value of 0 p/mL for the purposes of calculating the arithmetic mean of
triplicates (where at least one of the three readings was positive). All qPCR dataMed 2, 701–719.e1–e19, June 11, 2021 e18
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(> 5 p/mL) were used for modeling. Any values ranging from 1-5 p/mL were replaced
with a value = LLD (i.e., 5 p/mL). Any data point that was negative but preceded a
positive data point was replaced with a value = LLD (i.e., 5 p/mL); otherwise negative
data points occurring after any positive data point but not preceding a positive data
point were treated as 0 p/mL. PMR was then calculated using a linear model fitted to
log10-transformed qPCR data.
27 On day of CHMI for both VAC063A and VAC063B,
all volunteers were inoculated by midday. Therefore, for modeling purposes, morn-
ing follow-up bleeds were taken to occur at 9:00am (i.e., dC+1 was 0.9 d post-infec-
tion), and the evening bleeds were taken to occur at 6:00pm (i.e., 0.37 d later). As
previously, fitted lines were constrained to pass through the known starting parasi-
temia, calculated from the results of the limiting-dilution-based assay of the number
of viable parasites in the inoculum, and a weight-based estimate of each volunteer’s
blood volume (70 mL/kg).40 PMR was modeled for all volunteers that underwent
blood-stage CHMI, given they all had R 5 data points above the LLQ (the criterion
for proceeding to model the PMR).40Modeling of Antibody Kinetics
See Data S2A.Computational Analysis of Systems Serology Data
Spearman and Pearson correlation coefficients were used as indicated in the corre-
sponding Figures. For assessing the statistical significance, Benjamini-Hochberg
correction for multiple hypothesis testing was used. Random forest regression using
the ‘randomForest’ package of R was used to model DOD or IVGI based on the sys-
tems serology data. To take into account that some volunteers are in both Group 5
and Group 7, we used a leave-one-volunteer-out cross-validation framework that
yielded 13-folds. For each volunteer, the model was built on data of the remaining
volunteers and then used to predict the phenotype of the holdout volunteer. The
model prediction for the phenotype was compared to the observed phenotype
based on the Pearson’s product moment correlation coefficient and corresponding
P values (R function ‘cor.test’). The random forest regression was repeated 100 times
and the correlation coefficients and P values are shown in Figures S10D and S10E. To
assess the importance of the features within the leave-one-volunteer-out cross-vali-
dation framework, 100 repetitions of a recursive feature elimination (RFE) were per-
formed for each of the 13-folds. In each repetition, a random forest model is gener-
ated for the full feature set, and recursively the feature with the lowest importance
determined via the mean decrease in mean squared error is removed. For each of
the recursively obtained models, the out-of-bag mean squared error in prediction
is determined and the feature set corresponding to the best performing model is
chosen. Overall, we count how often a feature is chosen in the final feature set.
The regressionmodel was compared to amodel that was trained and tested for shuf-
fled phenotype labels. An R notebook (analysis_Rh5.Rmd) for the analysis is avail-
able as Data S2B.e19 Med 2, 701–719.e1–e19, June 11, 2021
